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ABSTRACT 
 
 
Aging can be defined as the accumulation of changes affecting the 
maintenance of homeostatic processes over time, leading to functional decline 
and increased risk for disease and death. In its simplicity, aging is the system-
wide deterioration of an organism. Genetic studies have identified many potential 
molecular mechanisms of aging including DNA damage, telomere shortening, 
mitochondrial dysfunction, increased oxidative stress, uncontrolled inflammation, 
and hormone dysregulation (reviewed in [1]). However, in reality, aging is likely to 
be a combination of some (or potentially all) of these mechanisms. 
Interestingly, aging and metabolism are tightly coordinated. Aging is a 
major contributor to metabolic decline and related diseases, including type 2 
diabetes, metabolic syndrome, and cancer. One of the best characterized 
metabolic pathways implicated in aging is the insulin/IGF-1 signaling (IIS) 
pathway. Downstream signaling components of the IIS pathway receptor have 
been well studied and include an interconnected network of signaling events that 
regulate many physiological outputs. However, less is known about the role of 
upstream signaling components and how intracellular pathways and physiology 
are regulated accordingly. In Part I, I present my work towards understanding 
upstream IIS pathway components using a systems biology approach. The goal 
of this study is to gain insight into the redundancy and specificity of the insulin 
gene family responsible for initiating IIS pathway activity in Caenorhabditis 
elegans. The information gained will serve as a foundation for future studies 
 viii 
dissecting the molecular mechanisms of this pathway in efforts to uncouple the 
downstream signaling and physiological outputs.  
The clear impact of metabolism on aging and disease stimulated 
questions regarding the potential of promoting health and longevity through diet 
and dietary mimetics. Recent findings indicate reduced food intake, meal timing 
and nutritional modulation of the gut microbiome can ameliorate signs of aging 
and age-associated diseases. Aging, therefore, is also the result of dynamic and 
complex interplay between genes of an organism and its environment. In Part II, I 
will discuss my efforts to gain insight into how diet influences aging. This 
preliminary study has demonstrated that diet can affect lifespan in the model 
organism, C. elegans. Additionally, we observe diet-specific effects on drug 
efficacy that, in turn, modulates C. elegans lifespan and reproduction. The 
implications of these experiments, while limited, illustrate a potentially greater 
role in diet- and drug-mediated effects on lifespan.  
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INTRODUCTION 
 
Caenorhabditis elegans as a model system  
 Dissecting the mechanisms of aging is almost impossible in humans given 
the long lifespan, genetic variability and complexity of diet. Therefore scientists 
have longed turned to model organisms as a system to investigate aging. A 
number of excellent model systems have been developed for aging research 
including the budding yeast Saccharomyces cerevisiae, the fruitfly Drosophila 
melanogaster, the mouse Mus musculus and the roundworm Caenorhabditis 
elegans. C. elegans was established as an aging model animal system in the 
1970s and has probably become the most widely used for aging studies [2], [3]. 
C. elegans offers multiple unique advantages as a model organism, such as 
physiological simplicity (959 cells), short life cycle (~3 days, egg to egg), 
reproducible lifespan (~2 weeks), and short reproductive span (~6 days). C. 
elegans can be easily and cheaply propagated in the laboratory by feeding 
bacteria on standard agar plates [4], [5]. In addition, large, isogenic populations 
of C. elegans can be grown and visualized in liquid culture, which allows for 
testing of many biochemical compounds on physiology. 
C. elegans are very amenable to genetic manipulations. Mutations can be 
induced in the animal through the use of chemicals (ethyl methane sulfonate), 
light (UV), or transposon-based methods, for example. The self-fertilizing 
capabilities of hermaphrodites, short generation times, and the abundance of 
progeny (~300 per worm) allow for quick isolation of genotypes and phenotypes. 
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These features allow for single-gene manipulations that can be directly tested for 
phenotypic effect using simple, well-defined assays that measure lifespan, brood 
size, and developmental timing [6], [7]. For instance, single genes have been 
identified that can significantly increase lifespan by over 100% [8]–[10].  Powerful 
forward and reverse genetic tools have also been established for use in C. 
elegans allowing for large, comprehensive and systems-level studies [5], [11]. 
Changes in gene expression can also be measured using high-throughput 
sequencing technologies such as RNA sequencing. C. elegans can be grown 
monoxenically, which offers the possibility of testing individual bacterial species 
for their role on aging [12]. In addition, the C. elegans diet can also be genetically 
manipulated to study the effect of dietary components ([13], [14] reviewed in 
[15]).  
Genetic and physiological manipulations to C. elegans are also easily 
tractable. in vivo examination of tissues, proteins and single genes is possible as 
C. elegans is transparent and simply requires the application of dyes or 
fluorescent reporters to visualize [16]–[20]. Animals can then be observed 
directly with the use of dissecting microscopes [19], [21]. Changes in tissue 
integrity and fat composition can also be quantitatively measured [22]–[24]. 
Additionally, many image analysis tools are available that automate measures for 
animal size, fat content, behavior and lifespan [25]–[29].  
C. elegans was the first multicellular organism to have its genome 
sequenced and, as a result, its genome is highly annotated and likely best 
understood. Surprising to most, C. elegans homologs have been identified for 60-
2
80% of human genes. Based on predictive surveys, ~42% of human disease 
genes have an ortholog in C. elegans; some of which, when mutated or knocked 
down, mimic morphological and/or functional defects of disease symptoms [30], 
[31].  In addition, its complete cell lineage is mapped providing a great tool for 
research on how genes influence cell fate, for example. A nervous system wiring 
diagram has also been constructed for all 302 neurons in the hermaphrodite [19], 
[21]. 
 C. elegans share many similarities in aging with higher eukaryotes. The 
survival curves of worms and humans, for instance, share the same shape, 
despite differences in their lifespans [6], [32], [33]. Hallmarks of aging also seem 
conserved between worms and humans. C. elegans undergo muscle atrophy, 
increased susceptibility to infection and cognitive decline with age [34], [35]. 
Additionally, the molecular mechanisms that regulate longevity in C. elegans are 
highly conserved with genes and pathways in humans (reviewed in [36]). As a 
result, studying longevity in C. elegans has profoundly impacted therapeutic 
applications and our understanding of human aging. 
  
3
PREFACE TO PART I 
 
 
SUMMARY 
 
Several factors influence longevity of an organism including genetics, the 
environment and diet. In Part I, I introduce a genetic pathway, the highly 
conserved insulin/IGF-1 signaling (IIS) pathway, which greatly influences 
longevity across species (Chapter 1). Studies examining the IIS pathway in many 
model organisms have continued to illustrate its key role in regulating longevity. I 
discuss the components and conservation of the IIS pathway with an emphasis 
on two main components: the receptor and its ligands. Chapter 1 serves as an 
introduction to my thesis research towards understanding the interactions 
between C. elegans IIS pathway ligands and physiology (Chapter 2). From this 
study and others, examining the insulin gene family by expression and mutation 
has revealed complex orchestration of physiology by the insulin ligands. In the 
last Chapter, I share my thoughts on how the insulins are functioning and what 
future directions would be most informative for gaining greater insight into this 
gene family (Chapter 3). 
 
Chapter 2 has been published as: 
Ritter, AD; Shen, Y; Fuxman Bass, J; Jeyaraj, S; Deplancke, B; Mukhopadhyay, 
A; Xu J; Driscoll M; Tissenbaum HA; Walhout AJ (2013). Complex expression 
dynamics and robustness in C. elegans insulin networks. Genome Res. 23, 954–
965. doi: 10.1101/gr.150466.112 
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For data presented in Chapter 2: 
Arnab Mukhopadjay, Bart Deplancke, Marian Walhout and Heidi Tissenbaum first 
conceived the project. Arnab Mukhopadjay and Bart Deplancke cloned a subset 
of promoters. Yuan Shen and Sankarganesh Jeyaraj performed the cloning 
created transgenic lines. Some strains were provided by the CGC, which is 
funded by NIH Office of Research Infrastructure Programs (P40 OD010440). Jian 
Xu and Dr. Monica Driscoll provided insulin RNAi constructs. 
 
I analyzed all expression patterns, did the phenotypic analyses, made the figures 
and wrote the published manuscript together with Marian Walhout and Heidi 
Tissenbaum. Juan Fuxman-Bass assisted me with TsOC analysis and statistics.  
 
For research presented in Part I, I was supported by the NIH Ruth L. Kirschstein 
National Research Service Award (NRSA) Individual Predoctoral Fellowship 
(AG041605). 
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PART I 
 
Complex expression dynamics and robustness in 
C. elegans insulin networks 
 
6
PART I, CHAPTER 1 
 
The insulin/IGF-1 signaling pathway 
The IIS pathway is critical for monitoring the macroenvironment and 
orchestrating a complex network of molecular mechanisms that modulate the 
appropriate physiological response. The IIS pathway regulates fundamental 
processes including growth/development, metabolism, reproduction, stress 
response and longevity [37], [38]. Interestingly, these physiological outputs are 
closely linked. For example, loss-of-function mutations in insulin signaling in both 
vertebrates and invertebrates lead to increased lifespan along with increased fat 
storage and improved stress response [39]. In humans, deregulation of this 
pathway can lead to age-associated diseases, such as type 2 diabetes, 
cardiovascular disease and cancer.  
The highly conserved IIS pathway is mediated by a complex and highly 
integrated network [40]. In mammals, upon insulin/IGF-1 binding, the receptor 
undergoes autophosphorylation and catalyzes phosphorylation of scaffolding 
adaptor proteins, such as the IRS family [41]. Activated IRS tyrosine 
phosphorylation sites act as docking sites for SH2 domains of cellular proteins. 
SH2-domain proteins initiate interactions with signaling molecules that activate a 
diverse series of intracellular pathways, including PI(3)K/Akt activation, MAPK 
kinase cascade, mTOR pathways and downstream protein-kinase C (PKC)/NF-
kB pathway. The IIS pathway ultimately impinges on FOXO transcription factors 
that regulate their target genes [40], [42].  
7
There are two key components to the IIS pathway: the insulin/IGF ligands 
and their receptors. Homologues of the insulin/IGF-1 receptor have been 
identified in Drosophila and C. elegans, as well as metazoan marine sponges 
[43]–[46]. However, while at least three insulin/IGF-1 receptors exist in 
vertebrates, only one receptor has been identified for Drosophila and C. elegans, 
the insulin/IGF-1 receptor (dInR) and DAF-2, respectively [38].  The insulin/IGF-1 
receptor belongs to a family of receptor tyrosine kinases and, in vertebrates, the 
insulin, IGF-I and insulin receptor-related receptor (IRR) all function as receptors 
for insulin/IGF ligands. Homodimeric and heterodimeric hybrid receptors can 
form and bind both insulin and IGF-1 with different affinities, depending on the 
insulin isoform [41]. While the binding of insulin to its receptor is complex, most 
mammalian studies illustrate the coexistence of high and low affinity binding 
sites. Dissociation studies have shown the existence of negative cooperativity 
between binding sites indicated by the accelerated dissociation of pre-bound 
ligand in the presence of unlabeled ligand [47]–[50]. 
The human genome encodes ten insulin-like peptides, including insulin, 
IGFs and relaxins, which together form a protein family called the insulin 
superfamily [51]. Drosophila melanogaster has eight insulin-like peptides, or 
DILPs [52]–[54]. Remarkably, the C. elegans genome encodes 40 insulin-like 
genes [55]–[58]. The human insulin gene encodes a 110-amino acid precursor, 
preproinsulin, which is translated in the endoplasmic reticulum and consists of 
four domains that are highly conserved across phylogeny: the signal peptide, A-
chain, B-chain and C-peptide. Proteolytic cleavage by a signal peptidase 
8
removes the signal peptide from preproinsulin to yield proinsulin, and three highly 
conserved disulfide bonds form between the A- and B-chains with the aid of ER 
chaperone proteins. After proper folding, the proinsulin precursor undergoes 
further cleavage to remove the C-peptide. The matured 51-amino acid insulin 
protein and the free C-peptide are then packaged in the Golgi. Insulin is stored in 
secretory granules as a hexamer of insulin peptide arranged as three dimers 
[59], [60]. Upon changes in nutrient availability, specifically glucose, amino acids 
and fatty acids, insulin is released from the cell via exocytosis where it circulates 
in the vascular system until binding its receptor [61]. All members of the insulin 
superfamily contain at least the A- and B-chain, although the length can be 
variable, and at least two of the conserved disulfide bonds. Historically, insulin 
was characterized to control carbohydrate and lipid metabolism, IGFs were 
mainly involved in growth and development and relaxins were involved in 
reproduction. However, classical genetic and functional genomic studies have 
revealed highly interconnected signaling between pathways modulated by these 
ligands [40].  
While we have seen remarkable progress in dissecting intracellular 
signaling pathways responsible for outputs of the IIS pathway, the molecular 
basis for specificity of intracellular activity is still not fully understood. In order to 
dissect these molecular mechanisms, researchers have turned to model 
organisms in efforts to gain better resolution.  
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The IIS pathway in Caenorhabditis elegans 
The discovery of the IIS pathway in C. elegans emerged from studies on 
dauer regulation and longevity. In response to unfavorable environmental 
conditions (i.e. high temperature, crowding and low food), C. elegans larvae 
undergo dauer arrest (Fig. 1.1). The IIS receptor, daf-2, and FOXO transcription 
factor, daf-16, were first characterized from a forward genetic screen designed to 
isolate mutants exhibiting deregulation of dauer arrest [62], [63]. These mutants 
illustrated dauer-constitutive and dauer-defective phenotypes, respectively. Not 
long after the identification of daf-2 and daf-16 genes, age-1, the C. elegans 
ortholog of the phosphoinositide 3-kinase (PI3K) p110 catalytic subunit, was 
isolated from a screen for long-lived animals [9], [64], [65]. Genetic epistasis 
experiments later illustrated daf-2, daf-16 and age-1 to be part of the IIS pathway 
leading to subsequent identification of pathway components [38], [44], [66]–[68]. 
These studies also revealed mutations in daf-2 resulted in a remarkable lifespan 
extension twice that of wild-type animals [8], [45]. To date, the IIS pathway 
remains the best characterized regulator of longevity across species.  
Further interrogation of the IIS pathway revealed even more conservation 
in IIS-mediated physiology. For instance, daf-2 mutants illustrate increased fat 
content compared to wild-type animals; a phenotype attributed to changes in fat 
metabolism driven, at least in part, by fat- genes and metabolic regulators that 
upregulate metabolic processes including fatty acid desaturation and lipolysis, 
acyl-CoA and alcohol dehydrogenases, and glyoxylate cycle [69]–[71]. In 
addition, daf-2 mutants illustrate increased stress resistance to many stressors 
10
 
 
 
 
 
 
  
 
 
 
 
 
FIGURE 1.1: The life cycle of C. elegans. In a favorable growth environment, C. 
elegans develop from an egg through progressive larval stages (L1-L4) until 
reaching the adult stage. In an unfavorable growth environment, C. elegans enter 
a diapause stage (L2d-dauer) and remain as a dauer until the environment 
becomes favorable for growth. An unfavorable environment is defined by a high 
concentration of secreted pheromone, higher temperature and/or low food 
availability.   
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including heat and oxidative stress, to name a few [72]–[74]. Mutants of daf-2 
also illustrate extended reproductive span [74], [75]. While some studies illustrate 
daf-2 mutants show delayed progression of age-associated neural decline, this is 
challenged by behavioral studies that illustrated impaired chemotaxis learning 
behaviors [76]–[79].  
There are a few physiological differences among mammals and 
invertebrates. While in mammals, deregulation of the IIS pathway leads to 
metabolic and age-associated disease, in C. elegans, as well as Drosophila, 
deregulation leads to dauer and longevity phenotypes. However, despite these 
physiological differences, the intracellular signaling cascade remains highly 
conserved, and like mammals, C. elegans IIS pathway modulates metabolism, 
reproduction, stress and development (Fig. 1.2) [38]. As a result, the easily 
measurable phenotypes in C. elegans, namely dauer and lifespan, have been 
adopted as proxies for IIS pathway activity.  
Both the gene and protein structures of insulin-like peptides in C. elegans 
and vertebrates are highly conserved and likely originated from a common 
ancestor [80], [81]. However, in mammals, it has been difficult to differentiate the 
activities of insulin, IGF and relaxins in their different contexts as signaling 
pathways downstream are highly similar and interconnected. Therefore, insulin-
like peptide signaling in C. elegans may translate to mammals allowing for 
greater understanding of signaling specificity. Given the short life cycle and ease 
of culturing, C. elegans can be considered one of the best model organisms to 
utilize for determining how the IIS pathway contributes to physiology.  
12
 
 
 
 
 
 
 
 
 
FIGURE 1.2: Insulin/IGF-1 signaling is conserved across species. Worms and 
flies have a single orthologue of the mammalian insulin/IGF-1 receptor tyrosine 
kinases, called DAF-2 and insulin receptor (InR), respectively. Downstream 
components such as PI3-kinase and FOXO are conserved in worms, flies and 
mammals. Under active IIS signaling, DAF-16/FoxO transcription factor is 
negatively regulated by phosphorylation and sequestered in the cytosol. This 
regulation is conserved across species (modified from [171]). 
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The expanded C. elegans insulin-like gene family 
While the amino acid sequence of insulin is variable among species, the 
positions of the disulfide bonds are highly conserved across species [80]. 
Researchers utilized the conservation of amino acid sequence and protein 
structure to comprehensively identify forty insulin-like genes (ins-1 through ins-39 
and daf-28; henceforth referred to as insulins) in C. elegans [56]–[58]. 
Interestingly, many of the insulins are organized in clusters of 3-7 along the 
chromosomes (Fig. 1.3). Insulins within a cluster tend to have closer sequence 
similarity than between members of a different cluster. However, with a range of 
25-40% amino acid identity in the A- and B-peptide regions, the genes in the 
cluster are still highly divergent [56]. The clustering, tandem arrangement and 
closer sequence similarity suggests these genes arose from recent gene 
duplication events and that they may still be evolving. Further analyses 
comparing the insulin gene family of C. elegans with other ancestral 
Caenorhabditis species, for instance C. briggsae, will provide further insights into 
the evolution of this gene family. 
The biochemical processing and physical binding of C. elegans insulins to 
its receptor remains largely unconfirmed. One biochemical study of INS-6 
illustrated conserved insulin folds and binding to the human insulin receptor [82]. 
Secretion of DAF-28 has been demonstrated and regulated by a conserved 
gene, asna-1, an ATPase that functions to regulate growth [83]. This suggests 
some shared physiological mechanisms of insulin release with mammals exist 
[84]. Although not direct evidence, DAF-16 is nuclear localized in the presence of 
14
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.3: Organization of insulin-like genes on C. elegans chromosomes. 
Many insulin-like genes (ins-) can be found in clusters of two to seven along the 
chromosomes. The relative distances between the genes are indicated (scale 
bar, 2.5 million bp). 
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a daf-28 mutation and the patterns of DAF-16 nuclear localization are similar to 
what is observed in daf-2 loss-of-function animals [57]. Together, these data 
illustrate that the interactions between insulins and DAF-2 are plausible and 
biologically relevant, although not comprehensively illustrated for the entire gene 
family. 
While the insulin receptor and downstream signaling pathways have been 
studied extensively through genetic approaches, little is known about the 
functionality of the C. elegans insulin gene family in regulating IIS pathway 
specificity. A vast majority of the insulins have no measured biological function, 
even upon loss or overexpression (Table 1.1). For some, genetic studies have 
shown insulins can regulate other insulins. Insulins can also function as receptor 
antagonists, agonists, or both, depending on a specific environmental condition 
examined [56], [71], [85]–[91]. A few insulins illustrate context-dependent 
phenotypes. For example, loss-of-function mutations in ins-1 cause defects in 
salt chemotaxis learning [79]. ins-7 loss-of-function mutants, along with increased 
lifespan, also have increased resistance to pathogenic infection [71], [92]. Loss-
of-function mutations in ins-3 leads to a reduced number of germ cells and 
decreased rate of dauer entry, although only in a sensitized daf-28 mutant 
background that already promotes dauer formation [87].  
  
How do we study gene families?  
Expanded gene families are generated from gene duplication events, an 
important process for the evolution of functional and organismal diversity. After 
16
 
 
 
 
 
 
TABLE 1.1: Previously published insulin phenotypes. Phenotypes reported in 
this table are compared to wild type (N2) and only include results from mutations, 
deletions, RNAi or overexpression in N2 backgrounds. References are indicated 
by superscript letters. For phenotypes in other mutant backgrounds (such as daf-
2), see column titled “Other.” 
 
 
 
 
  
17
duplication, the resulting identical paralogs diverge in both sequence and 
function. Neo-functionalization occurs when one paralog adopts a novel function 
that is not shared by the ancestral gene, while in sub-functionalization the 
ancestral function(s) are divided between the two paralogs [93], [94]. In addition 
to functional divergence, it can also be beneficial for paralogs to maintain (partial) 
redundancy, for instance to provide a buffer under adverse genetic or 
environmental conditions (Fig. 1.4) [95], [96]. Numerous gene families have been 
identified by whole genome sequencing and gene annotation. So far, only few 
families have been analyzed at a systems level, and the balance between 
divergence and redundancy is only beginning to be illuminated. For example, in 
C. elegans, basic helix-loop-helix transcription factors have extensively diverged 
in multiple functional parameters [97]. However, ETS transcription factors 
function redundantly in the mouse, by binding and regulating the same target 
genes [98].  
C. elegans live in the soil and are exposed to many environmental 
conditions [5]. C. elegans use the IIS pathway to respond to environmental cues 
adjusting development and lifespan accordingly. For example, growth and 
reproduction in the worm are directly influenced by food availability and other 
environmental conditions such as temperature and crowding [63], [99]. With this 
knowledge, I hypothesized that there is a “division of labor” between the 40 
insulins in C. elegans, as well as redundancy between some family members, 
which together enables a sophisticated and robust metabolic response during 
development, in physiology and to respond to environmental cues.  
18
 
 
 
 
 
FIGURE 1.4: Gene duplication leads to functional diversification and/or 
redundancy. In this network, each gene duplicate (gray node) regulates (edge) a 
function (colored node). During gene duplication, replicate genes can undergo 
(from left to right) subfunctionalization, the ancestral function is partitioned 
between paralogs to create a “division of labor”; neofunctionalization, one 
paralog evolves a new, advantageous function different from its ancestral 
function; sub-neofunctionalization, after subfunctionalization paralogs can gain 
new function; or redundancy, functional overlap is conserved between paralogs. 
Gene duplication events lead to redundancy and specificity in the network that 
can promote “fine-tuning” of the response to environmental stimuli. 
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Different studies rely on different methods to examine redundant 
interactions between gene family members.  Genetic redundancy can be inferred 
from computational or experimental approaches. Computationally, gene 
duplications can be examined by: 1) estimating increased dispensability, or 
centrality, of duplicates, whereby dispensability is defined by the probability a 
gene associates with an essential function; 2) quantitatively determining the 
fitness contribution of each duplicate; and/or 3) curating literature [100]–[104]. 
Experimentally, genetic redundancy is inferred with the use of classical epistasis 
analysis examining synthetic interactions. For instance, a comprehensive 
analysis of C. elegans Argonautes was conducted by knocking out combinations 
of all 27 genes. While all Argonautes bind to small RNAs, many perform specific 
roles at different steps in the same RNAi pathway or in different pathways all 
together. Conversely, a few, called secondary Argonautes, can be functionally 
interchangeable with other Argonautes. Interestingly, some elicit unique 
phenotypic consequences upon loss, such as chromosome segregation defects 
(csr-1) or reduced fertility (prg-1) [105].  
The most intuitive way to test redundancy and specificity in the insulin 
gene family would be by taking a classical genetic approach. This would require 
generating strains bearing a mutation in each insulin gene or performing RNA 
interference (RNAi) knockdown of each insulin gene and then testing for IIS-
related phenotypes including lifespan, metabolism, development and 
reproduction. In Drosophila, the use of this approach illustrated that the 
knockdown of individual insulin-like peptides (DILPS) confers no obvious 
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phenotypes. Severe phenotypes, such as lethality, are only observed upon loss 
of multiple DILPS. For instance, loss of dilp2 increases dilp3 and 5 transcripts 
and loss of all three leads to severe phenotypes under different conditions 
illustrating the functional redundancy and compensation between these genes 
[106], [107]. Testing multiple phenotypes and lifespan for 40 individual genes in 
C. elegans, however, is impractical. Importantly, if some insulins function 
redundantly, as I hypothesize, the loss of individual insulins might be masked or 
buffered by the function of another. If true, this would mean that double 
([40x40]/2 = 800 possible combinations), or even triple insulin mutants are 
required to be tested for all the different phenotypes. Therefore, I utilized a 
different strategy whereby I will take a comprehensive “systems approach.”  
 
Using a systems approach to dissect insulin function 
Genes that act redundantly are often co-expressed, at least in part. 
Therefore, we decided to annotate spatiotemporal and conditional insulin 
expression as a starting point to indicate which insulins may function together. C. 
elegans are transparent and transgenic animals carrying promoter-driving green 
fluorescent protein (GFP) constructs can be used to annotate spatiotemporal 
gene expression in living animals [17], [97], [108], [109].  
 Relationships between genes and the cells or tissues in which they are 
expressed can be visualized into expression networks. In such networks, “nodes” 
represent insulin genes and individual cells/tissues and “edges” link the gene to 
the tissue where it is expressed illustrating the relationship [97], [109]. Visualizing 
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gene expression into network models is highly useful as it provides an instant 
glimpse into the complexity of gene expression. Expression networks can be 
formatted to display all the cells/tissues in which each insulin gene is expressed 
(gene-centric) or a direct view on which genes are expressed in particular 
cells/tissues (tissue-centric). Further, expression networks can be analyzed 
computationally to quantify co-expression of the genes of interest. For this, a 
tissue overlap coefficient (TsOC) is calculated that is defined as the number of 
tissues shared between two insulin genes divided by the smallest of the total 
number of tissues where either insulin gene is expressed [110], [111]. The TsOC 
for a pair of insulin genes defines the overlap of their tissue expression. For 
example, insulins that exhibit complete overlap in tissue expression are assigned 
a value of 1, whereas insulins with no overlapping expression have a score of 0. 
In order to generate high-resolution tissue expression networks, two important 
tools are required. First, a high-throughput method is needed that will unveil 
spatiotemporal gene expression for each gene of interest. This is accomplished 
by: 1) using Gateway cloning of gene promoter fragments upstream of an open 
reading frame encoding the green fluorescent protein (GFP), and 2) creating 
transgenic C. elegans that harbor each construct. Previous studies have shown 
that the use of only gene promoter fragments provides a high-confidence proxy 
for endogenous gene expression [108]. Second, a controlled vocabulary is 
needed to confidently assign gene expression to different tissues and cells [97], 
[109].  
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Because C. elegans has a simple anatomy, invariant cell lineage, and 
transparent body, it is relatively easy to generate such a controlled vocabulary. I 
defined 23 categories (hereafter referred to as “tissues”), including intestine, 
vulva, body muscle, etc. Some tissues are specific (e.g. distal tip cells), and 
others are broad (e.g. head neurons). To generate insulin expression networks, I 
will study where (spatio) and when (temporal) each insulin is expressed during 
development as well as how each insulin gene expression changes when the 
transgenic animals are exposed to a variety of relevant environmental conditions. 
Insulins that are co-expressed either in development or under different conditions 
are more likely to function redundantly. Conversely, insulins with unique patterns 
of expression may have functionally diverged and attained specific functionalities 
(for example, only affecting one phenotype of the IIS pathway). Taken together, 
this will allow a comprehensive investigation of the C. elegans insulin-like family 
by modeling the expression network to predicting the function of individual insulin 
genes (see Part I, Chapter 2). 
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PART I, CHAPTER 2 
 
RESULTS 
 
Lack of pair-wise redundancy between C. elegans insulins in dauer 
formation 
We used dauer diapause, one of the main outputs of the IIS pathway, to 
explore the putative extent of redundancy and specificity in the insulin family. 
Loss-of-function mutations in the DAF-2 receptor result in a dauer-constitutive 
(Daf-c) phenotype [112]. We found that neither deletions in 12 insulins nor 
knockdown of any of the 40 insulins results in dauers (Fig. 2.1; Table 2.1). As 
some insulins have been reported to have antagonistic effects on the IIS pathway, 
we asked whether loss of individual insulins would prevent dauer formation. After 
dauer-inducing conditions, all mutants analyzed were capable of forming dauers, 
indicating that they are not dauer defective (Fig. 2.2). Together, these results 
indicate that no single insulin is the sole agonist or antagonist for coordinating 
dauer formation through the DAF-2 receptor. Next, we asked whether insulins 
may function in redundant pairs by knocking down each of the 40 insulins in the 
10 insulin mutants. However, none of the combinations of insulin mutants and 
insulin RNAi resulted in the formation of dauers (Fig. 2.1). This suggests there is 
no simple pair-wise redundancy between insulins in regulating dauer formation, 
but rather that more complex patterns of redundancy may be involved. 
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FIGURE 2.1: Examination of dauer formation upon insulin perturbation. Neither 
loss of individual insulins (columns), nor pairwise insulin perturbation by 
combined mutation and knockdown (rows) results in dauer formation. 
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FIGURE 2.2: Individual insulin mutants form dauers in starvation-induced 
conditions similar to wild-type (N2), indicating that they are not dauer defective. 
Dauer formation is illustrated as the average of duplicate experiments; data is 
normalized to wild-type (N2) dauer formation. Additional data can be found in 
Table 2.1. 
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TABLE 2.1. Examination of dauer phenotypes of insulin mutants. Dauer 
phenotype data from Figure 6. Top – Daf-c assays. The total number of non-
dauers and dauers from duplicate experiments. Data are normalized to wild type 
(N2) dauer formation. Bottom – Daf-d assays. Data represents the average from 
two replicates where starvation-induced dauers were counted after 1% SDS 
survival. Data are normalized to wild type (N2) dauer formation. n.d. = not 
determined. 
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Complex patterns of insulin expression 
To determine spatiotemporal insulin expression patterns during 
development and under a variety of relevant physiological and environmental 
conditions, we cloned the promoters of each of the 40 C. elegans insulins 
upstream of an open reading frame encoding GFP, and generated transgenic 
animals as described [113]. Promoter activity is often a faithful proxy of 
endogenous gene expression gene; therefore, we refer to insulin promoter 
activity as “insulin expression” [97], [108], [109].  
We annotated insulin expression using a controlled vocabulary to enable 
the direct comparison between different genes and between different tissues [97], 
[109]. In hermaphrodites, 36 of 40 insulin promoters conferred GFP expression in 
six major tissue types: nervous system, muscle, reproductive tissue, epithelia, 
the alimentary system and coelomocytes (Fig. 2.3). These were subcategorized 
into specific cells/tissues, totaling 19 different tissue/cell types (Fig. 2.4). We 
found that most tissues express multiple insulins (Fig. 2.4A), and, conversely, 
that most insulins are expressed in multiple tissues (Fig. 2.4B). Four insulin 
promoters did not drive GFP expression in hermaphrodites: ins-19, ins-24, ins-31 
and ins-37. However, ins-19 and ins-31 did exhibit GFP expression in males (Fig. 
2.5) [114]. Altogether, we detected activity for 38 of 40 promoters (95%). 
Spatiotemporal expression patterns have previously been reported for 17 
insulins [56], [57], [70], [71], [86], [87]. Our data recapitulate the expression 
patterns for nine of these (Table 2.2): ins-1, ins-3, ins-4, ins-7, ins-8, ins-9, ins-11, 
ins-18, and ins-33. However, for all nine, we observed expression in additional 
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TABLE 2.2: Previously published insulin expression patterns. Expression in a 
tissue is indicated by blue if it is observed only in this study, orange if only in 
other recorded studies, or green if observed in both. A * indicates expression 
patterns observed that were not previously published (see Supplemental Fig. 
S2). Tissues are assigned as follows: I, intestine; DTC, distal tip cell; GS, 
gonadal sheath; M, muscle; HN, head neurons; BN, body neuron; TN, tail 
neuron; VNC, ventral nerve cord; P, pharynx; H, hypodermis; SU, 
spermatheca/uterine valve; C, coelomocytes; S, spermatheca; V, vulva/vulva 
muscle/vulva neurons; U, uterus; R, rectum. 
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FIGURE 2.3: Cartoon of a C. elegans hermaphrodite with colors illustrating 
insulin expression in six major tissue types: nervous system (green), reproductive 
tissue (blue), muscle (gray), epithelial tissue (orange), coelomocytes (pink), and 
alimentary system (purple).  
 
  
30
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.4: Spatial expression of the 36/40 insulins expressed in C. elegans 
young adult hermaphrodites. (A) Number of insulins expressed in each tissue/cell 
type. Colors correspond to the six major tissue types in Figure 7. (B) Number of 
tissues/cell types in which each insulin is expressed. 
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FIGURE 2.5: Insulin expression in males. (A) Pins-19::GFP transgenic strains 
show GFP expression in head neurons (arrowhead). (B) Pins-31::GFP transgenic 
strains show GFP expression in the gonad (arrowhead). 
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tissues. For seven insulins we found different expression patterns than reported 
previously. For example, we observed ins-22 expression in head neurons, but 
not in the ventral nerve cord, body and tail neurons as reported previously [56]. 
Differences in insulin expression may result from the inclusion or exclusion of 
particular regulatory sequences in the promoter fragments used. Alternatively, 
expression pattern annotation may not have been examined with the same 
resolution in different studies and weak expression may have been missed. 
Indeed, for two strains, we observed additional expression patterns in previously 
published strains that were not reported (Fig. 2.6). 
Next, we examined the expression patterns for the 36 insulins expressed 
in hermaphrodites. Almost all insulins are expressed in neurons, consistent with 
the reported importance of neuronal insulin signaling in different organisms [115]. 
Head neurons express the greatest number of insulins (n=32, Fig. 2.4A). We 
grouped head neuron expression into three classes: sensory (including amphid 
neurons), pharyngeal and ring motor/interneurons (Fig. 2.7A). As amphid 
sensory neurons are exposed to the environment, many can be visualized by DiI 
staining [116]. We stained all transgenic strains with DiI and annotated any 
overlap between DiI staining and GFP expression. DiI staining was also used to 
provide orientation for determining which insulins were expressed in each 
category of head neurons (Fig. 2.7B). In total, 25 insulins are expressed in 
sensory neurons, 14 of which are expressed in amphid neurons, 23 insulins in 
ring motor/interneurons and 13 in pharyngeal neurons. Twenty-two insulins are 
expressed in two or more general types of head neurons (Fig 2.7C). 
33
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 2.6: Previously published Pins::GFP transgenic strains illustrating GFP 
expression in the vulva (white arrowhead). This tissue expression was missed in 
previous publications. 
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FIGURE 2.7: Insulin genes are expressed in head neurons. (A) Cartoon of three 
head neuron categories: sensory (red), pharyngeal (black), ring 
motor/interneurons (green). (B) Two examples: Pins-1::GFP exhibits GFP 
expression in many head neurons including amphid sensory neurons (arrow 
heads) and ring interneurons (circle arrow). Pins-28::GFP exhibits GFP 
expression in pharyngeal, but not amphid neurons (arrows). Amphid neurons 
were visualized by DiI staining (red). Yellow indicates that GFP expression 
(green) occurred in amphid neurons (red). (C) Summary of neuronal insulin 
expression in three types of head neurons: sensory, ring motor/interneuron, and 
pharyngeal. Insulins that exhibited overlapping GFP expression and DiI staining 
are defined as having amphid expression. 
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Dynamic changes in insulin expression during development 
To determine insulin expression changes during development, we 
annotated GFP expression at each larval stage (L1-L4), in young adults and 
mature adults. A value of 1 or 0 was assigned to each tissue/cell type to indicate 
the presence or absence of GFP expression, respectively (Table 2.3). To capture 
tissue expression changes through development, we visualized the data into 
bipartite expression networks [97], [109]. These networks contain two types of 
nodes: genes and cells/tissues. Edges link the gene to the tissue in which it is 
expressed. We visualized insulin expression patterns into networks for each of 
the developmental stages by using Cytoscape [117] (Fig 2.8; Fig. 2.9A). Several 
tissues showed loss of insulin expression as the animals progress through 
development. For example, in 11 transgenic strains, GFP was expressed in the 
pharynx in early larval stages but only three insulin promoters remained active in 
the adult pharynx (Fig. 2.9B). Most tissues showed increased insulin expression 
during development, particularly when animals entered the L4 stage. For 
example, 14 insulins are expressed in the distal tip cell at the young adult stage 
but only one (ins-13) exhibited expression early, at the L2 stage (Fig. 2.9B). 
Some tissues/cells are formed later in development, which explains later 
expression; for instance the vulva, spermatheca, uterus and gonad have not fully 
developed until late-L4 and adult stages. Overall, insulins exhibit dynamic stage- 
and tissue-specific expression patterns during development (Fig. 2.10). 
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TABLE 2.3: Insulin expression annotation. GFP expression was examined in 
each Pins::GFP line throughout the animal. Expression in a tissue is indicated by 
a “1”; whereas, no expression is indicated by a “0”. Tissues are assigned as 
follows: I, intestine, PI, partial intestine; DTC, distal tip cell; GS, gonadal sheath; 
HM, head muscle; BM, body muscle; VM, vulva muscle; EM, enteric muscle; SN, 
sensory head neuron; RIM, ring interneuron/motor head neuron; PN, pharyngeal 
head neuron; BN, body neuron; VN, vulva neuron; TN, tail neuron; VNC, ventral 
nerve cord; P, pharynx; SU, spermatheca/uterine valve; C, coelomocytes; S, 
spermatheca; U, uterus; R, rectum. 
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FIGURE 2.8 Insulin expression networks for each developmental stage. Bipartite 
networks of spatial expression of 36 insulins in the following stages of C. elegans 
hermaphrodites: L1, L2, L3, L4, Adult (~3-4 day old adult with eggs). See Fig. 12 
for Young Adult stage. Circles represent insulins; squares represent cells/tissues 
as follows: S, spermatheca; C, ceolomocytes; R, rectum; HM, head muscle; VM, 
vulva muscle; DTC, distal tip cell; U, uterus; BM, body muscle; H, hypodermis; 
EM, enteric muscle; P, pharynx; BN, body neuron(s); VN, vulva neuron(s); TN, 
tail neuron(s); VNC, ventral nerve cord; HN, head neuron; PN, pharyngeal 
neuron(s); RIM, ring/intermotor neuron(s); SN, sensory neuron(s); I, intestine. An 
edge defines GFP expression of an insulin in that tissue. The network is 
organized as follows: (top to bottom) insulins with no neuronal expression; non-
neuronal tissues (excluding the intestine); insulins with neuronal and non-
neuronal tissue expression; neuronal tissues and the intestine, insulins with only 
neuronal and/or intestinal expression. 
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(continued from previous page) 
 
 
 
FIGURE 2.9: Insulin expression networks illustrate dynamic tissue activity. (A) 
Bipartite network connecting 35 insulins to cell/tissues at the young adult stage. 
Pins-20::GFP animals did not exhibit GFP expression at the young adult stage 
and were excluded. Circles represent insulins; squares represent cells/tissues: S, 
spermatheca; C, ceolomocytes; R, rectum; HM, head muscle; VM, vulva muscle; 
DTC, distal tip cell; U, uterus; BM, body muscle; H, hypodermis; EM, enteric 
muscle; P, pharynx; BN, body neuron(s); VN, vulva neuron(s); TN, tail neuron(s); 
VNC, ventral nerve cord; PN, pharyngeal neuron(s); RIM, ring/intermotor 
neuron(s); SN, sensory neuron(s); I, intestine. Purple circles indicate insulins that 
change in spatial expression through development; orange circles are insulins 
that do not change. The network is organized as follows: (top to bottom) insulins 
with no neuronal expression; non-neuronal tissues (excluding the intestine); 
insulins with neuronal and non-neuronal tissue expression; neuronal tissues and 
the intestine, insulins with only neuronal and/or intestinal expression. (B) 
“Dartboards” depicting tissue-centered view of insulin expression. Each ring 
represents a developmental stage, starting from the center: larval stages L1, L2, 
L3 and L4, young adult and adult with eggs (~3-4 day old adult). Each slice 
represents an insulin with strong GFP (black), weak GFP (gray) or no GFP 
(white) expression. Left – dartboard profile of the pharynx (P); Right – dartboard 
profile of the distal tip cell (DTC) 
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FIGURE 2.10: Tissue-centered dartboards illustrating insulin expression. Each 
ring represents a developmental stage, starting from the center: larval stages L1, 
L2, L3 and L4, Young Adult and Adult (~3-4 day old adult with eggs). Each slice 
represents an insulin with strong GFP (black), weak GFP (gray) or no GFP 
(white) expression. Tissues are assigned as follows: HN, head neurons; I, 
intestine; HM, head muscle; TN, tail neuron; VNC, ventral nerve cord; BN, body 
neuron; R, rectum; C, coelomocytes; VN, vulva neuron; VM, vulva muscle; DTC, 
distal tip cell; P, pharynx; S, spermatheca; U, uterus; H, hypodermis; EM, enteric 
muscle; BM, body muscle; SU, spermatheca/uterine valve; GS, gonadal sheath.  
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Conditional dynamics of insulin expression 
The IIS pathway not only modulates C. elegans development, it is also 
utilized to respond to environmental conditions [112]. We investigated insulin 
expression in young adult transgenic strains exposed to relevant conditions 
including heat stress, dauer diapause, starvation, aging, oxidative stress, and 
glucose, and visually examined changes in GFP expression (Fig 2.11A; Fig 2.12).  
Neither glucose nor oxidative stress affected insulin expression. However, 
we did observe changes in insulin expression with the other conditions. The 
greatest number of insulins changed expression in dauers (n=14) and with age 
(n=14); major phenotypic outputs of IIS pathway. Increased and decreased 
insulin expression was observed for all conditions, except heat stress. For 
example, ten insulins decreased in expression in dauer, whereas four 
increased.  We also observed stage-specific responses in insulin expression. For 
instance, GFP expression increased dramatically after heat stress in L4 Pins-
4::GFP hermaphrodites, but not in young adults (Fig. 2.12B). In total, four genes, 
ins-3, ins-7, ins-11 and ins-30, exhibited changes in GFP expression in three 
conditions tested, four changed in two, 17 in one, and 14 did not change in any of 
the conditions tested. 
We also observed specific conditional changes in spatial expression 
(Fig. 2.11; Fig. 2.13). Pins-27::GFP, for example, exhibits GFP expression in 
muscle in all stages of development, and muscle expression decreased as the 
animals age (Fig. 2.11B). This could reflect a loss of muscle integrity known to 
occur during the aging process [34] and perhaps the Pins::27::GFP transgenic 
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FIGURE 2.12: Environmental effects on insulin expression. (A) Controls for 
conditional expression changes. Environmental conditions (see Methods) were 
tested to ensure that each would illicit a biological response from the animal. A 
reporter transgenic strain harboring a gene previously illustrated to respond to 
the respective condition was used as follows: Phsp-4::GFP for heat stress, Pgst-
4::GFP for paraquat, Pacdh-1::GFP for starvation, daf-16a::GFP for glucose. (B) 
ins-4 stage-specific responses to heat stress. Under normal conditions (no 
stress), L4 and young adult stage Pins-4::GFP hermaphrodites do not express 
GFP in the hypodermis (top left and top right). After heat stress, GFP is 
expressed in the hypodermis of L4 (bottom left) but not young adult (bottom right) 
hermaphrodites (white arrowheads). 
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FIGURE 2.13: Gene-centered dartboards illustrating insulin expression. Each 
ring represents a developmental stage or environmental condition, starting from 
the center: larval stages L1, L2, L3 and L4, Young Adult and Adult (~3-4 day old 
adult with eggs), heat stress, dauer, starvation and aging. Each slice represents 
a tissue with GFP expression (black), no GFP (white), GFP increase (red) or 
GFP decrease (blue). The number in the center indicates the insulin (i.e. 1 = ins-
1; d28 = daf-28). Tissues are assigned as follows: HN, head neurons; I, intestine; 
HM, head muscle; TN, tail neuron; VNC, ventral nerve cord; BN, body neuron; R, 
rectum; C, coelomocytes; VN, vulva neuron; VM, vulva muscle; DTC, distal tip 
cell; P, pharynx; S, spermatheca; U, uterus; H, hypodermis; EM, enteric muscle; 
BM, body muscle; SU, spermatheca/uterine valve; GS, gonadal sheath. 
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strain may provide a convenient marker to observe the aging process in living 
animals. Another example is in Pins-4::GFP animals where GFP expression 
changes similarly in different conditions: it increases dramatically in the 
hypodermis of young adults after starvation and aging animals (Fig. 2.11B). 
 
Comparing insulin expression patterns 
We quantified the degree of expression overlap for pair-wise combinations 
of insulins at each stage of development using a Tissue Overlap Coefficient 
(TsOC) similarity index (Fig. 2.14A) [97], [109]. TsOC values were clustered to 
visually identify genes that share high overlap versus those with little to no 
overlap in expression. At the young adult stage, we observed two clusters of 
insulins that share high overlap (Fig. 2.14B). The lack of pair-wise gene 
expression clustering correlates with the lack of pair-wise phenotypic redundancy, 
indicating that there may be more complex patterns of redundancy. We next 
investigated to what degree expression overlap changes through development. 
Of 630 possible insulin pair-wise comparisons (of 36 insulins examined), 37 pairs, 
consisting of 22 genes, had a TsOC of zero throughout development, illustrating 
their mutually exclusive expression. There was no insulin that exhibited a unique 
expression pattern (i.e., with a TsOC=0 with every other insulin). Further, 
although eleven insulin pairs consisting of 19 insulins exhibited complete overlap 
(TsOC=1) in a single larval stage, none exhibited complete overlap throughout 
development. Even though the degree of overlap between insulins changed from 
one larval stage to the next, most remained consistently higher or lower in their 
degree of expression overlap (Table 2.4). 
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FIGURE 2.14: Comparing insulin gene expression illustrates specificity and 
overlap in expression. (A) Tissue overlap coefficients (TsOCs) define the 
expression overlap between all pairwise insulins (A and B). Insulins (circles) 
exhibit GFP expression (edges) in C. elegans tissues (squares). A TsOC of 1 
indicates complete overlap while a TsOC of 0 indicates no overlap in expression. 
(B) Tissue overlap matrix using TsOC scores from the young adult stage. Red 
boxes highlight visually delineated clusters of highly overlapping insulins.  
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TABLE 2.4: Ranking of TsOC scores for each transgenic strain throughout 
development. “Gene pair” describes the pair-wise comparison between insulins. 
TsOC scores for all pair-wise combinations are ranked by life stage. Life stages 
are defined as: L1, L2, L3, L4, Young Adult and Adult (~3-4 day old adult with 
eggs). Each pairwise combination has been averaged across all 6 stages (AVG 
of ALL).  
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To capture the overall degree of overlap of the insulin expression patterns 
throughout the lifetime of the animal, we averaged the TsOCs between all stages. 
The top 5% TsOC values (TsOC ≥ 0.68) were distributed among 18 genes (Fig. 
2.15A). Some insulins (e.g., ins-4), shared high overlap with many other genes in 
this group, while others, (e.g., ins-26), shared high overlap with only two other 
genes.  
Next, we quantified similarity in conditional expression. We first assigned 
the following values for each condition: -1 for a GFP decrease/loss, 0 for no 
changes, and +1 for a GFP increase/additional tissue expression. Then, using a 
Spearman rank test, we compared all pair-wise combinations to identify insulins 
that correlate in their response. A conditional overlap of 1, for example, indicates 
that two insulins responded the same under every condition tested. In contrast, a 
score of -1 indicates that two insulins responded oppositely. Of 325 pair-wise 
combinations (among 26 insulins that exhibit a conditional change), 23 insulin 
pairs, consisting of 18 genes, shared a score of -1, thus responding oppositely. 
Thirty-six pairs, consisting of 18 genes, shared a score of +1, thus responding 
the same under the conditions tested. Finally, no pair exhibited high correlation 
both during development and under different conditions (Fig. 2.15B, red box). 
This suggests that no insulins are completely coexpressed over all conditions 
and stages. 
 
ins-8 expression increases upon loss of ins-7 
Intuitively, one might expect that close homologs that share high 
expression overlap may exhibit redundancy. When we compared pairwise insulin 
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FIGURE 2.15: Comparing insulin gene expression TsOC scores. (A) Co-
expression network of insulins (circles) that share the top 5% average TsOC 
scores through six larval/adult stages. An edge represents an average TsOC ≥ 
0.68; maximum average TsOC = 0.89 (ins-4 and ins-5). (B) No gene pairs (red 
box) share the same expression in both conditional (as measured by a 
Spearman rank test) and developmental tissue expression. TsOC is presented 
as an average of the six TsOC values for each developmental stage. 
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protein sequence identity to their average TsOC scores we did not observe a 
correlation between sequence and expression similarity (Fig. 2.16A).  
One outlying pair of insulins, ins-7 and ins-8, is both similar in sequence 
and in spatiotemporal expression (Fig 2.16). To test putative redundancy 
between these insulins, we first examined developmental timing and dauer 
formation in single ins-7(tm1907) or ins-8(tm4144) mutants and found no 
differences compared to wild type animals (Fig 2.1, Fig 2.2, Table 2.1). Close 
paralogs can compensate each other’s loss by an increase in expression [95], 
[118]. We examined endogenous ins-7 expression in an ins-8 mutant and vice 
versa and found that while loss of ins-8 did not result in a change in ins-7 
expression, loss of ins-7 resulted in a ~15-fold increase in ins-8 expression (Fig. 
2.16C). In a recent study it was reported that endogenous ins-7 is expressed at 
higher levels than ins-8 throughout development [119]. ins-7 and ins-8 are less 
than 1kb apart in the genome; therefore, in the ins-7(tm1907), the ins-8 gene 
resides in closer proximity to the (stronger) ins-7 promoter (Fig. 1.3). To test 
whether this could explain the observed increase in expression, we examined 
ins-8 expression upon ins-7 RNAi in both wild type (N2) and RNAi hypersensitive 
rrf-3(pk1426) mutants [120]. Again, we observed an increase in ins-8 expression 
upon perturbation of ins-7, albeit to a lesser extent (Fig. 2.16D. Therefore, the 
up-regulation of ins-8 in the ins-7 mutant background is not due to the close 
proximity of the two genes. This data also illustrates that RNAi targeting ins-7 
does not elicit a complete knockdown.  
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ins-7 expression increases upon dauer formation (Fig. 2.16B). However, 
ins-7 mutants do not have any defects in dauer formation (Fig. 2.1; Fig. 2.2; 
Table 2.1). Since ins-8 expression increases upon perturbation of ins-7, we 
asked if ins-8 functions redundantly with ins-7 in modulating dauer formation. The 
genomic proximity of the two genes precludes the generation of double mutants. 
However, neither RNAi of ins-7 in an ins-8 mutant, or vice versa, either in wild 
type or in rrf-3(pk1426) mutants conferred a dauer formation phenotype or any 
other phenotypes including lethality, L1 arrest, or developmental delay compared 
to vector control RNAi or wild type animals (data not shown). 
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FIGURE 2.16: Divergence, overlap and compensation in expression between 
ins-7 and ins-8. (A) There is no clear positive correlation between the degree of 
overlap in expression through development (average TsOC) and sequence 
similarity of insulins. ins-7 and ins-8 (red dot) are the only pair that share both 
high sequence similarity and high TsOC. TsOC is presented as an average of the 
six TsOC values for each developmental stage. (B) ins-7 and ins-8 exhibit high 
overlap in expression under standard laboratory conditions (first 6 rings, from L1 
to adult) but exhibit different conditional changes in expression (4 outermost 
rings). Red = GFP increase; blue = GFP decrease; black = no change in GFP 
expression, white = no GFP observed. (C) In the absence of ins-7 (orange), ins-8 
(purple) expression is increased. (D) ins-8 increases in both wild type (N2) (p < 
0.0001) and rrf-3(pk1426) mutants (p = 0.054) upon RNAi knockdown of ins-7. 
mRNA abundance was measured by qRT-PCR for (C) and (D). Triplicate repeats 
from biological duplicate samples were measured. One biological sample is 
illustrated here. The error bar indicates variation between triplicates. 
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PART I MATERIALS AND METHODS 
 
Strain Maintenance  
All strains were maintained at 15°C using standard C. elegans techniques [4]. 
Males were generated by heat shocking L4 larvae at 30°C for 6 hours. 
 
Generation of Pins::GFP transgenic animals 
We used gene predictions available in WormBase WS150 
(http://ws150.wormbase.org). In total, 22 of the 40 promoter constructs were 
obtained from the Promoterome collection [121]. The remaining promoters were 
PCR amplified and cloned as described [121]. Primer sequences are provided in 
Table 2.5. Transgenic animals were generated by microparticle bombardment as 
described [122]. For each Pins::GFP reporter construct, 2-6 independent lines 
were obtained. At least two lines were examined for GFP expression and the line 
that showed highest transmission was used further. Nineteen of 40 Pins::GFP 
strains harbored the GFP construct integrated in the genome. For all 
nonintegrated lines, 50-100 animals were analyzed to capture each component 
of the expression pattern. An increase in expression was recorded if the level of 
GFP dramatically increased and/or if expression in additional tissues was 
observed, while an expression decrease was defined by a dramatic reduction in 
GFP levels and/or a complete loss of expression in at least one cell/tissue type. 
All strains are available from the C. elegans Genetics Center, or upon request. 
 
 
Genotyping 
The genotype of each transgenic line was confirmed by PCR (Table 2.5), 
followed by DNA sequencing. One gravid animal was added to 5µL of solution 
containing 2µL 20mg/mL proteinase K and 100µL lysis buffer (30mM Tris pH8, 
8mM EDTA, 100mM NaCl, 0.7% NP40, 0.7% Tween 20) and incubated at 60°C 
for 1hr followed by 95°C for 15 minutes. Each 50µL PCR reaction included 1µL 
dNTP, 5µL 10X Buffer, 0.4µL of each Fwd and Rev primers (at 25 µM), 0.2uL 
Taq polymerase, 1µL MgCl2, 32.4µL water, 10µL template obtained from worm 
lysis. PCR conditions included 34 cycles of (95°C for 2 minutes 45 seconds, 56° 
for 1 minute, 72°C for 3 minutes) followed by 68°C for 7 minutes, 10°C for 30 
minutes.  
 
RNAi 
Bacterial feeding of RNAi clones was performed as described [123]. Control 
(empty vector) and unc-22 clones were used as negative and positive controls, 
respectively. Each clone was verified by PCR and sequence analysis.   
 
Dauer analyses  
For analysis of dauer constitutive phenotypes, wild type and mutant animals were 
grown on vector and daf-2 RNAi for one generation at 25°C. Approximately 10 
adults from the F1 progeny were added to new RNAi culture plates and allowed 
to lay eggs for 6-8 hours at 25°C. Plates containing eggs were incubated at 25°C 
and analyzed after 2-3 consecutive days by counting dauers and non-dauers. 
Dauers were determined by survival of 1% SDS treatment for 15 minutes. To test 
for a dauer defective phenotype, two young adult animals were placed on OP50 
plates and left at 25°C or 27°C to reproduce. Plates were checked daily to 
examine the bacterial lawn. 3-4 days after no food remained, the number of 
animals on the plate were scored and then 1.5mL of 1% SDS was added to each 
plate. After 15 minutes, the number live thrashing animals (i.e. dauers) were 
counted. Assays were performed in duplicate. 
 
Pins::GFP expression pattern annotation  
GFP expression was examined in 40-50 animals by fluorescence microscopy 
using a Zeiss Axioscope 2 plus as described previously [97], [122], [124]. 
Temporal expression patterns were classified into six stages: four larval stages 
(L1-L4), young adult (no eggs) and ~3-4 day adult with eggs. Developmental 
stages were defined by the length and number of cells in the gonad 
(wormatlas.org). Spatial expression patterns were classified into 19 categories 
that correspond to tissues, cell types, organs, and individual cells. Temporal and 
spatial expression was standardized into a binary code, where “1” represents 
expression detected and “0” indicates no expression detected. 
 
Tissue overlap analysis  
Tissue overlap coefficient (TsOC) analysis was performed as described [97], 
[124], [125], with minor modifications to annotate more specific tissues. Nodes 
were defined as insulins and the cell/tissue in which they are expressed. TsOC 
was analyzed for each pair of nodes by a geometric formula [126]. 
Conditional expression analysis 
Each stress was determined sufficient by testing with genes known to respond to 
the respective condition (Fig. 2.12A). Oxidative stress: 1mL 200mM paraquat 
was added to 10mL OP50-seeded NGM plates. Young adults were added and 
incubated at 20°C for 6 hours. Verified using Pgst-4::GFP transgenics [127]. 
Glucose: 1mL 2% glucose was added to 10mL OP50-seeded NGM plates. 
Young adults were added and incubated at 20°C for 1-, 6-, 12- and 24-hours. 
Verified using daf-16a::GFP transgenics [128]. Heat stress: L4 larvae and young 
adults were placed on OP50-seeded NGM plates and incubated at 30°C for 6 
hours. Plates were not stacked to assure heat was equally distributed among all 
plates. Verified by using Phsp-4::GFP transgenics [129]. Starvation: L4 and 
young adult animals were washed twice using 1X M9 buffer then placed on 
peptone-free plates without bacteria. Animals were incubated at 20°C for 24 
hours. Verified by using Pacdh-1::GFP transgenics [130]. Dauer: We obtained 
dauers by allowing plates to starve. Strains were grown at 20°C until no food 
remained. Dauers were picked 3-4 days after plates were starved. Aging: one-
day old adults were placed on OP50-seeded 5-fluorodeoxyuridine (FuDR) plates. 
GFP expression was recorded on days 5, 10, and 15. In all experiments, the 
presence of GFP expression was translated into a numbers where “1” represents 
a GFP increase, “0” represents no change in GFP, and “-1” represents GFP 
decrease. Correlations (i.e. conditional overlap) were determined using 
Spearman’s rank test. 
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Quantitative RT-PCR 
For all qRT-PCR experiments, strains were maintained at 20°C and mixed late-
L4/YA stage animals were used. Worms were collected and washed 2x with 
sterile 1x M9 buffer (3g KH2PO4, 6g Na2HPO4, 5g NaCl, 1mL 1M MgSO4, H2O to 
1 liter; Sterilize by autoclaving). Supernatant was removed and 10x volume of 
TRIzol reagent (Invitrogen, USA) was added to the worm pellet. Pellet was frozen 
at -80°C until RNA extraction. Total RNA was purified by phenol:chloroform 
extraction and ethanol precipitation followed by column purification using a 
RNeasy Mini Kit (Qiagen, USA). The quality of RNA isolated was determined by 
checking the 28S and 18S RNA on an agarose gel and quantity measured by 
NanoDrop® ND-1000 Spectrophotometer. 1µg of total RNA was used to make 
cDNA using the SuperScript® III First Strand Synthesis Kit (Invitrogen, USA). 
The expression of ins-7 and ins-8 genes was checked by quantitative PCR using 
the SYBR® Green PCR Master Mix (Invitrogen, USA) and StepOnePlusTM Real-
Time PCR System (Applied Biosystems, USA). Samples were analyzed three 
times in triplicate from two independent worm cDNA preps and two different 
cDNA sample dilutions. mRNA levels were normalized for act-1 mRNA and 
expressed as log2 fold change compared to controls. Significance was 
determined by Student’s t-test. Primers used for RT-PCR experiments can be 
found in (Table 2.5).  
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TABLE 2.5: Primer sequences for all primers used for genotyping or performing 
RT-PCR experiments (see Materials and Methods).  
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PART I, CHAPTER 3 
 
DISCUSSION 
In this study, we report widespread and dynamic spatiotemporal 
expression of C. elegans insulins during development and under different 
physiological and environmental conditions. Not all expression patterns may 
completely capture endogenous insulin expression for several reasons. First, the 
promoter fragments used may lack regulatory elements required for expression 
in some tissues or to repress expression in others. Second, expression was 
annotated to the resolution of individual cells in some but not all tissues. 
Annotating at the level of individual cells is challenging, especially in neurons 
where insulins are abundantly expressed. Thus, the overlap in expression for 
neuronal insulins may be lower than estimated here. Third, we did not observe 
GFP expression in the germline, most likely because of transgene silencing [131]. 
Finally, insulins are secreted peptides that may act cell-nonautonomously [83], 
[132]. Nonetheless, we provide both a first comprehensive dataset as well as a 
set of transgenic strains, both of which enable future studies of the functional 
dynamics of the entire C. elegans insulin gene family in vivo. 
Several examples illustrate how the insulin expression patterns provide a 
resource for the derivation of functional hypotheses. First, the expression 
patterns of individual insulins can likely be used to predict specific functions. For 
instance, we found that ins-3 is expressed in the distal tip cell, spermatheca and 
the spermatheca-uterine valve. Previously, it has been shown that perturbations 
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of ins-3 result in defects in germline proliferation, and that this is due to function 
of ins-3 in the soma [87]. Second, changes in expression of individual insulins 
can likely be used to infer specific functions as well. For example, it has been 
shown that daf-28 is involved in dauer formation and we find that its expression is 
turned off in dauers ([86], this study). Third, the expression data can likely be 
used to derive hypotheses about complex functional redundancies. For instance, 
14 insulins change in expression as the animals age; 8 of which increase and 6 
of which decrease in expression. Future studies of which insulins are receptor 
agonists versus antagonists will be important to derive hypotheses regarding 
combinatorial insulin function in lifespan regulation.  
Remarkably, pair-wise combinations of insulin loss/knockdown did not 
result in defects in dauer formation. This could be due to inefficient insulin 
knockdown in neuronal tissues required for dauer formation [63]. Alternatively, 
there may be more complex patterns of redundancies between more than two 
insulins. The lack of 1:1 insulin relationships is supported by the observation of 
two clusters in the expression network, rather than simple pair-wise co-
expression patterns.  
Two insulins, ins-7 and ins-8, share high sequence similarity and 
expression overlap through development. We find that ins-8 levels increase in 
the absence of ins-7, but did not detect compensatory changes in ins-7 
expression upon loss of ins-8. Knockdown of ins-7 in an ins-8 mutant or vice 
versa did not affect dauer formation. However, loss of ins-7 slightly extends 
lifespan (Fig. 3.1) [71]. This suggests that, while ins-8 increases upon loss of ins-
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7, it cannot fully compensate for the loss of ins-7 in modulating longevity, further 
illustrating the lack of 1:1 relationships between insulins. Additionally, while loss 
of ins-7 extends lifespan, it does not recapitulate the dramatic lifespan extension 
caused by a loss-of-function in daf-2. Together, this data suggests that ins-7 and 
ins-8 may genetically interact with other insulins. Alternatively, it is conceivable 
that the overexpression of ins-8 in the ins-7(tm1907) rather than the loss of ins-7 
may be responsible for the observed lifespan extension of ins-7 mutants, which 
would suggest that ins-8 is an antagonist whereas ins-7 is an agonist. However, 
dauer formation was not observed upon loss of ins-7 nor were ins-8(tm4144) 
mutants dauer defective (Fig. 2.1; Fig. 2.2). This illustrates that ins-8 is not likely 
an antagonist. 
In the wild, C. elegans is exposed to a variety of environmental conditions. 
Food and temperature serve as modulators of dauer formation [133]. By entering 
dauer, development ceases until a favorable environment becomes available. 
Intuitively, differential insulin activity could ensure that a whole organism 
response, such as dauer formation, only occurs under specific conditions and not 
in response to any type of stress. Remarkably, we found that insulins that share 
high expression overlap during development are distinct from those that share 
similarities under different conditions (Fig. 3.2). This may reflect a need for 
specificity in coordinating development versus responding to different stresses. 
The expansion of the insulin family and its genetic wiring may provide the animal 
with a complex and highly organized repertoire of responses that can be tailored 
according to developmental or environmental need. In biological systems, 
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FIGURE 3.1: Lifespan analyses of insulin mutants. Lifespan phenotypes of ins-
8(tm4144) (red) and ins-7(tm1907) (green) lifespan as compared to N2 (blue). 
Lifespans were performed in duplicate at 20°C. Mean and maximum lifespans 
are as follows: N2=16.5 ±1; 23 days; ins-7(tm1907)=18 ±2, 28 days; ins-
8(tm4144)= 16 ±2, 23 days. Prism 5 was used to calculate and perform survival 
curve comparisons. Significance was determined using the log-rank (Mantel-Cox) 
test.  
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FIGURE 3.2: A co-expression network of the insulins (circles) that share the top 
5% average TsOC through six larval/adult stages (blue edge) and the top 5% of 
conditional overlap (COS; red edge). Distinct clusters are observed whereby no 
insulins are both connected through high TsOC and high COS. 
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different components can be interchangeable under certain conditions, but 
perform distinct functions under other conditions. Such redundancy, or 
degeneracy, contributes to the robustness, complexity and evolvability of a 
system [134], [135]. We propose that the C. elegans insulin family has evolved to 
attain a type of “block design”, a term used in combinatorial mathematics. An 
evolved block design can lead to the formation of different functional alliances in 
different cells for different developmental versus environmental conditions (Fig. 
3.3). Cooperative action between insulins may provide a robust framework for 
interpreting physiological and environmental cues and ensuring that the DAF-2 
receptor initiates the appropriate response. For instance, daf-28 and ins-6 
cooperate in modulating dauer formation. However, each insulin also functions 
specifically in dauer entry or exit, respectively [86].  
C. elegans likely utilize 40 insulins to achieve both specificity and 
redundancy to maintain fitness in a complex environment. The total possible 
number of combinations in different sets, for instance with 3, 4 or even more, is 
immense, and potentially provides the animal with a large and flexible repertoire 
of possibilities to recognize and respond appropriately to many environmental 
stimuli. Future studies will illuminate the generality of this observation for insulins 
in other nematodes, as well as other gene families in C. elegans and other 
complex multicellular organisms such as humans. 
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FIGURE 3.3: Model for complexity and robustness in gene families. A “block 
design” or “alliances” in insulins under a given condition. A colored node 
represents one insulin. An edge represents overlapping function. Different 
alliances allow for the appropriate response to different conditions (top row). 
Although different conditions likely require different insulins, some (yellow node) 
may always be shared between conditions. Loss of single insulin activity does 
not cause a phenotypic affect due to redundancy (bottom left) and/or 
compensation (bottom right) with other insulins. 
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Concluding remarks and future directions 
Why do C. elegans have a large insulin gene family and how do they 
function? To answer “why” the expansion of this gene family occurred will take 
comparative evolutionary studies, including other Caenorhabditis species, to 
begin to elucidate. “How do the insulins function?” is a question that will require 
further dissection of the molecular mechanisms shared among this gene family 
and the insulin receptor. From our study and others, examining the insulin gene 
family by expression and mutation has revealed complex orchestration of 
physiology by the insulin ligands. The insulins appear to be functioning as a 
combinatorial network: a system of signals that orchestrate a systematic 
physiological response. We now need more sensitive and directed studies to 
further elucidate this gene family. In the following, based on the current literature 
and from our study, I will share my thoughts on how the insulins are functioning 
and what future directions would be most informative for gaining greater insight 
into this gene family. 
 
Redefining insulin “function” 
For many insulins, loss of function or overexpression has yielded no 
measureable phenotype. Perhaps unobserved phenotypes are in part because of 
the phenotypes themselves being analyzed: dauer and lifespan require 
coordinated and systematic changes in metabolism, gene expression, and tissue 
reorganization within the entire organism. As a result, there is an elaborate 
orchestration of molecular events that must occur in order for the animal to dauer 
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and/or increase lifespan. While some loss of single insulin genes can cause 
changes in dauer and lifespan, the majority do not. To gain granularity on the 
function of the insulins, more specific, context-dependent contributions of 
individual insulins should be measured.  
Mutations in the DAF-2 receptor lead to dramatic changes in metabolism 
[136]. Dauer, the phenotypic readout for metabolic change, is the response to 
harsh environmental conditions (i.e. high temperature, low food and crowding) 
[133]. Dauer is a whole-organismal response whereby development ceases, the 
cuticle and oral orifices are sealed, and pharyngeal muscles do not pump. Dauer 
is a highly programmed, step-wise physiological process that takes up to 72 
hours until complete [137]. Changes in metabolism that enable the animal to 
dauer thus occur in systematic steps. However, we do not know how or exactly 
which metabolic pathways are modulated to cause dauer and if changes to these 
pathways can be uncoupled. What is the influence of the insulins on metabolism? 
How many insulins modulate metabolism? Mutating one insulin that, for instance, 
alters the flux through a single metabolic pathway, may not be sufficient to induce 
a whole-organismal response like dauer. However, the combinatorial loss of 
insulins altering multiple metabolic pathways may be a synthetic interaction 
resulting in a measurable change in whole organismal physiology such as dauer. 
For instance, single loss-of-function mutations in daf-28 or ins-6 result in no 
dauer phenotypes at an ambient temperature and in the presence of food. Upon 
loss of both daf-28 and ins-6, however, ~40% animals form dauers in the same 
conditions. Genetic studies using gain-of-function mutations, illustrate that daf-28 
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influences metabolism to promote dauer, even in optimal conditions. 
Interestingly, ins-6(-), as well as a few others, have been reported to have 
increased fat content when compared to wild-type animals [138]. What metabolic 
changes do the loss of each insulin illicit? Does the change in fat content 
contribute to the dauer phenotype observed in the daf-28; ins-6 double mutant? 
Further, are the metabolic phenotypes of these mutants similar to that observed 
for daf-2(-) animals, that also have increased fat content and a dauer constitutive 
phenotype? With the advent of metabolomic technologies, studying the influence 
of the insulins on metabolism will be more feasible and tractable.  
To date, no single insulin mutation or overexpression recapitulates the 
daf-2(-) phenotype. With the recently developed use of clustered, regularly 
interspaced, short palindromic repeats (CRISPR)-associated endonuclease Cas9 
to target genomic sequences, we now have the ability to precisely modify 
genomes using an efficient, low cost approach. With new genome editing 
technologies, the genetic manipulative possibilities are endless [139]–[141]. For 
example, gene deletions for each insulin, and in all possible combinations, can 
be generated and subsequently interrogated. One could also attempt to 
sequentially knock out all of the insulin genes to determine whether the daf-2(-) 
phenotype can ever be fully recapitulated.  
 
Investigating insulin protein expression and function 
Do all 40 insulins encode a functional protein? In mammals, proprotein 
convertases, PC1 and PC2, process precursors of the insulin peptide. 
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Computational predictions and mutational analyses identified four homologous 
enzymes in C. elegans: three PC1 homologs, AEX-5, BLI-4, and KPC-1, and one 
PC2 homolog, EGL-3 [142]–[144]. Two of these enzymes, EGL-3 and KPC-1, 
have been demonstrated to successfully process, at least in part, four insulin 
proteins, INS-3, INS-4, INS-6 and DAF-28 in vivo. Kao et al generated a full-
length DAF-28::GFP protein and observed successful expression and secretion 
in vivo [84]. However, only one study has described the structure of an insulin, 
INS-6, and successfully illustrated that it binds and activates the human insulin 
receptor [82]. It is unknown if INS-6 can bind and activate the C. elegans 
receptor. These data support the fact that insulin genes can encode functional 
protein, and future studies will elucidate whether this is true for the remaining 
insulin family members. 
In mammals, insulin, IGFs and relaxins are synthesized and secreted from 
the pancreas, liver, and ovaries, respectively. Although, IGFs can be synthesized 
in a number of peripheral tissues and enter into systemic circulation [145]. In C. 
elegans, insulin-like genes show widespread patterns of gene expression with 
most being expressed in neuronal tissue and the intestine. Neurons, along with 
the intestine, have been illustrated to be the major tissues in which the IIS 
pathway modulates dauer and lifespan, respectively. Proprotein convertases 
involved in insulin processing are also expressed in neurons, intestine and some 
muscle cells [146]. In what tissues are the insulins synthesized and/or secreted? 
Will these tissues overlap with gene expression patterns reported for the insulin 
family? Studying the spatiotemporal expression of insulin protein in addition to 
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gene expression will be instrumental to gaining further understanding of their 
function.  
The extent to which insulins act cell autonomously or non-autonomously 
also remains unknown. However, there are at least two examples where an 
insulin is expressed under a specific condition in one tissue and affects 
physiology through interactions with a second, local tissue [147, 148]. In both 
models, environmental cues are first sensed by sensory neurons and these 
sensory neurons mediate insulin activity to other tissues. For example, INS-1 is 
released from the AIA when an odor is present. Under short odor exposure, ins-1 
inhibits downstream calcium transients in a different neuron, the AWC; however, 
after long odor exposure, ins-1 may completely suppress calcium transients even 
after odor removal. On the other hand, INS-1 acts in AIA interneurons, which 
receive direct synaptic inputs from sensory neurons and also send synaptic 
outputs to ASER. These results suggest that INS-1 secreted from AIA 
interneurons provides feedback to ASER to generate plasticity of chemotaxis. 
This feedback loop acts to tune sensory responses to external stimuli [147].  
A second study illustrated that the nervous system can also signal to the 
intestine. Under normal conditions, the nervous system secretes agonistic 
ligands, INS-4, INS-6 and DAF-28, to increase IIS signaling in the intestine thus 
sequestering intestinal DAF-16. Under unfavorable environmental conditions, 
antagonistic ligands, INS-1 and INS-18, and a decrease of agonistic ligands are 
secreted to decrease IIS signaling in the intestine thus activating DAF-16 to 
initiate dauer formation [148]. Neuropeptides can be considered hormones in that 
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they act as long range signaling molecules [58]. How far can the insulins travel in 
the worm? In C. elegans, insulins may be similarly released from cells and act 
some distance from their site of release. Understanding the signaling network of 
insulins from synthesis to site of action will further elucidate how this gene family 
modulates physiology. 
 
Investigating the insulin receptor and downstream signaling 
It has been proposed that DAF-2 is a bifunctional gene as daf-2 alleles 
can be grouped into two phenotypic classes based on pleiotorphy [74]. Given its 
multiple downstream effectors and diverse biological functions, is it possible that 
alternate forms of the DAF-2 receptor exist? There are six predicted isoforms of 
daf-2 [146]. In a recent study, two of these isoforms, daf-2a and daf-2c, were 
examined for their ability to rescue daf-2 mutants. Interestingly, not only do these 
two isoforms illustrate different intracellular localizations, but also functional 
diversity: daf-2c only rescued avoidance behavior defects of daf-2 mutants, 
whereas daf-2a was effective in rescuing lifespan, dauer formation and 
thermotolerance [149]. The mammalian insulin receptor has a modular structure 
whereby two isoforms of the receptor differ slightly in their affinity for insulin and 
IGF [150]. As mammalian insulin/IGF receptors can form hybrid dimers, perhaps 
the different isoforms of daf-2 can dimerize forming many more receptor 
combinations in C. elegans. If this were true, this may reveal a DAF-2 signaling 
network and reveal how DAF-2 is able to coordinate many different signaling 
components. 
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Alternatively, some question whether other DAF-2-like receptors could be 
present. There is at least one report of a daf-2-independent insulin effect [151]. In 
mammals, G-protein coupled receptors (GPCRs) bind relaxins, members of the 
insulin superfamily. One computational study interrogated the C. elegans 
genome for insulin receptor-like domains using the extracellular domain 
sequence of insulin receptors and related RTKs from human to worm and found 
56 putative matches [152]. Interestingly, many of the 56 genes clustered along 
the genome, a common product of recent duplication events. Are any of these 
functional DAF-2-like receptors? Can C. elegans insulins also bind GPCRs? 
Given the strong evidence of combinatorial features of the insulin signaling 
network, it would be worthwhile to genetically investigate this possibility. 
Is DAF-2 expressed similarly on every cell in C. elegans? The redundant 
yet specific biological effects of the IIS pathway could also be attributed to 
differences in receptor distribution among tissues with different capacities for 
metabolic response to a given signal. It is known that, while the insulin receptor is 
expressed on every mammalian cell, the number of receptors per cell varies from 
40 on erythrocytes to 300,000 on adipocytes and hepatocytes [153], [154]. As a 
result, some tissues including the liver, fat and muscle are more important for 
insulin signaling in mammals than others [155], [156]. In C. elegans dauer 
formation, genetic mosaic analyses illustrate a larger contribution of daf-2 
signaling originates in neuronal cell lineages [157]. Intestinal IIS pathway activity 
has also been implicated to be an important determinant of longevity [71], [158]. 
Comparing the number of receptors, and also what form of the receptor, occurs 
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on different cell types may be insightful in determining on which tissues insulin 
signaling is most important and how signaling may differ between tissues. 
The IIS pathway has been illustrated to function within a network of 
signaling events composed of multiple inputs and branchpoints [159]. For 
instance, the TOR pathway similarly controls development, metabolism and 
lifespan in C. elegans. A conserved component of TOR signaling, daf-15/raptor, 
functions to mediate daf-16-regulated dauer and metabolic phenotypes. Further, 
DAF-16 can negatively regulate daf-15/raptor [160]. In addition, mutations in daf-
16 and rsks-1, a ribosomal protein S6 kinase involved in a branch of the TOR 
signaling pathway, synergistically prolong lifespan 5-fold. Tissue-specific 
epistasis analyses suggest intestinal DAF-16 is activated by interacting signals 
between daf-2 signaling and rsks-1 in the germline [161]. In addition to the TOR 
signaling pathway, the IIS pathway also interacts with the TGF-β signaling 
pathway that also regulates the dauer decision. The IIS pathway can be 
negatively regulated by the TGF-β pathway through a phosphatase, PDP-1, 
which also, interestingly, decreases expression of a subset of insulins [162]. At 
least one sequential signaling model has been proposed whereby environmental 
cues sensed by sensory neurons trigger TGF-β signaling which leads to DAF-16 
activation by antagonistic insulin expression. DAF-16 and a downstream TGF-β 
transcription factor, DAF-12, and then together initiate dauer formation [148].  
Further, hundreds of genes have been predicted to be regulated by DAF-16 and 
comprise functional classes including stress response, antimicrobials, steroid 
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synthesis, metabolism, lipid synthesis, protein and peptide degradation and 
signaling [70], [163].  
The variety of functions of the IIS pathway, and interconnected pathways, 
illustrate the importance of multiple systems that keep the animal living. This also 
reveals the extensive crosstalk and network wiring of signaling components 
downstream of DAF-2. How is intracellular activity of DAF-2 different upon 
binding of different insulins? Can we use the insulins to uncouple the molecular 
mechanisms, and thus physiology, downstream of the receptor? Gaining greater 
understanding of how insulin ligands specifically affect IIS pathway signaling will 
likely shed light on how the IIS signaling network is orchestrated. Further, as the 
function of the ten mammalian insulin superfamily members is not entirely solved, 
understanding the overlap and specificity of IIS pathway signaling via insulin-like 
peptides in C. elegans may provide a foundation for understanding pathway 
crosstalk between growth factors in mammals.  
 
Dissecting the insulin network 
Our study suggests insulins cooperate to provide a robust framework for 
interpreting physiological and environmental cues and ensuring that the DAF-2 
receptor initiates the appropriate response. C. elegans likely utilize 40 insulins to 
achieve both specificity and redundancy to maintain fitness in a complex 
environment. How would our proposed “block design” be physiologically 
attained? Previous data illustrates the IIS pathway activity is tissue-specific. For 
instance, restoring DAF-2 signaling in neurons alone brings the extended 
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lifespan of daf-2 mutants back to that of wild-type. Restored DAF-2 pathway 
signaling in muscles rescues only dauer arrest, also proving that dauer and 
lifespan phenotypes can be uncoupled [164]. Further, intestinal DAF-16 is 
sufficient to increase lifespan of short-lived daf-16(-) animals by 50-60%; 
whereas, expression only in neurons moderately increases lifespan of daf-16(-) 
animals by 5-20% [158]. DAF-16 expression in the epidermis mediated cell-
nonautonomous effects on germline proliferation [165]. Further, as discussed 
previously, cell non-autonomous activity has been illustrated whereby insulin 
secretion from one tissue exerts a physiological response in a nearby or distant 
tissue [147], [148]. The tissue-specific IIS pathway activity agrees with the tissue-
specificity of insulin gene expression. Therefore, it is likely tissue-specificity of 
insulin binding likely plays a big role in how the IIS pathway coordinates 
physiology. Perhaps while insulins that bind DAF-2 receptors in the intestine 
modulate stress response and metabolism, insulins that bind receptors in the 
neurons may coordinate development and behavior. Different cell types express 
different genes. We know there are downstream signaling interactions between 
the IIS pathway and other pathways [40], [162]. It is conceivable that intracellular 
signaling mechanisms may differ significantly depending on the cell-type and 
other signals being received by a cell, and this may be sufficient to elicit specific 
physiological effect by a tissue in response to an environmental condition. 
Further studies testing tissue- or cell-specific rescue of insulins and measuring 
which downstream target tissues insulin-DAF-2 interactions occur will add 
significant depth to our working model. 
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Interestingly, IIS pathway tissue-specificity studies also revealed that DAF-
16 activity in signaling cells upregulates DAF-16 in specific responding tissues 
[158]. Further examination of the proposed “FOXO-to-FOXO” signaling revealed 
that DAF-16 activity in the intestine activates DAF-16 in other tissues in part by 
down-regulating ins-7 expression in the intestine [71]. In addition, many insulins 
are up-regulated in a daf-2(-) background suggesting that the IIS pathway can 
cause changes on insulin expression [70], [91]. Therefore, another network 
model has also been proposed: a biological neural network in which insulins 
regulate other insulins, referred to as the ILP-to-ILP network. Are insulins 
directing feedforward or feedback signals to other insulins? Feedforward and 
feedback signaling motifs among insulin-like genes are utilized by other species 
[71], [107], [132], [161]. Could ILP-to-ILP regulation elucidate how the proposed 
combinatorial effects occur? The idea of intercommunication between the 
insulins prompted a recent large-scale network analysis of insulin activity that 
examined global insulin gene expression changes by measuring mRNA levels of 
all 40 insulins in 35 insulin loss-of-function mutants. Of the possible 1190 
interactions between the insulins, 101 interactions were observed, and regulation 
had both a positive and negative effect on insulin gene expression [91]. Network 
analyses investigating relationships between the number of regulators (in-
degree) versus the number of targets (out-degree) revealed that the insulins 
appear to display hierarchical regulation, whereby some insulins have few inputs 
and many outputs, some have equal number input and output and others have 
many inputs with few outputs. Further functional examination of interactions 
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between deletion mutants illustrated both additive and synergistic and highlight 
functional relationships and differences among insulins in regulating dauer entry. 
Regulatory and genetic interactions were then combined to examine overall 
network architecture. Measuring node connectivity revealed parallel signaling 
pathways and significant compensation upon insulin loss [91]. The ILP-to-ILP 
regulatory and phenotypic circuit thus further illustrates network robustness, and 
agrees with our network model, at least in the context of regulating dauer, 
whereby the combinatorial efforts of insulins ensure the appropriate physiological 
response to the environment.  
Context-dependent and cell/tissue-specific functional studies of insulin-like 
peptides in C. elegans remain unexplored. Given the complexity of the network 
with which insulins are interacting, it is likely these functional analyses will only 
provide some additional information towards why and how this large gene family 
contributes to animal physiology. Additionally, we know very little about the 
regulation of insulin expression. How is this gene family regulated? Further 
examination of what transcription factors regulate gene expression, as well as 
factors regulating protein secretion, will be very informative of exactly the cues 
for which the insulins respond and how the IIS pathway may regulate insulins 
themselves.  
To fully appreciate the extent of gene diversification, a comprehensive, 
multiparameter network of this gene family is necessary. Current insulin networks 
are constructed from few parameters such as genetic interactions or, as in my 
study, gene spatiotemporal expression patterns. However, these models ignore 
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aspects of insulin functionality such as gene regulatory interactions, transcription 
factor spatiotemporal expression patterns, insulin-receptor interactions, or protein 
spatiotemporal expression. Therefore, inclusion of these parameters in future 
model networks will generate a more holistic understanding of insulin function. 
While these integrated networks have yet to be delineated for the majority of 
gene families, including the insulins, there are a few cases in which paralog 
divergence has been examined using this approach [97].  
 
The C. elegans insulin gene family as a model for organismal complexity 
and robustness 
Most genes in any genome are dispensable for viability. For instance, 
single gene deletions have revealed that in yeast only 1,100 of the 6,000 genes 
(18%) are essential [166]. Similarly, in worms 1,700 of 20,000 genes (8.5%) 
confer lethality when knocked down by RNAi [167]. Numerous functional screens 
have been performed using the yeast deletion collection and by RNAi in worms. 
Remarkably, combined these screens identified a ‘function’ for only a small 
proportion of genes, and that organisms are highly robust to genetic 
perturbations.  
Robustness can be defined as a key property of evolutionary systems that 
allows a system to maintain function against internal and external perturbations 
[135]. Functional maintenance does not imply homeostasis, but rather a return to 
the original state or entrance into a new and different stable state. Robustness 
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has been explored using networks capturing cellular functions, metabolic 
networks and host-pathogen interactions, to name a few [168]–[170].  
Biological systems are inherently complex and robust, but also exhibit 
fragility, especially over time. As mentioned previously, aging, in its simplicity, is 
the system-wide deterioration of an organism, and aging occurs among every 
living thing, even in the midst of robustness. The IIS pathway is one of the 
genetic contributors to aging and thus involved in maintaining organismal 
robustness over time. Revealing the functional contributions of the insulins in C. 
elegans will allow us to dissect the molecular mechanisms of the IIS pathway. 
Perhaps studying insulin function over time may give some insight into how these 
mechanisms are orchestrated, particularly in modulating metabolism, with age 
and in disease.   
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PREFACE TO PART II 
 
SUMMARY 
Aging can be modulated, at least in part, by diet. In Part II, I discuss how 
diet, dietary mimetics and other chemical compounds affect C. elegans lifespan 
(Chapter 4). I present my preliminary research that exemplifies how interactions 
between different diets and a drug can influence animal physiology (Chapter 5). 
Finally, in the last chapter, I discuss the implications of my research and future 
directions for gaining a greater understanding of the interactions between diet, 
drugs and C. elegans physiology (Chapter 6). 
 
Data regarding the contribution of B12 to C. elegans lifespan, discussed in 
Chapter 4, was generated in a previously published manuscript: 
 
Watson, E; Macneil, LT; Ritter, AD; Yilmaz, LS; Rosebrock, AP; Caudy, AA; 
Walhout, AJM (2014). Interspecies systems biology uncovers metabolites 
affecting C. elegans gene expression and life history traits. Cell. 156(4), 759–770. 
doi: 10.1016/j.cell.2014.01.047 
 
 
The data presented in Chapter 5 was generated with the help of Gabrielle Giese. 
Gabrielle Giese performed the Comamonas DA1877 mutant screen, sequencing 
of mutants and performed replicate experiments for brood size, bacterial growth 
and lifespan experiments. Marian Walhout and I conceived the project. I 
performed all data analysis and experiments, except for the mutant screen. The 
data presented in Part II are preliminary and unpublished findings. 
102
PART II 
 
Diet-specific drug effects on C. elegans 
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PART II, CHAPTER 4 
 
INTRODUCTION 
Diet significantly impacts metabolism and physiology. Diet may also 
contribute appreciably to longevity. For instance, dietary restriction (DR) has 
been illustrated to have beneficial effects on longevity and is perhaps one of the 
most studied dietary contributors of aging [1]. DR, defined as the reduction of 
nutrient intake without causing malnutrition, can lead to significant increases in 
lifespan across vertebrate and invertebrate species [2]. While the exact 
molecular mechanisms of DR are not fully elucidated, examining DR in C. 
elegans has demonstrated basic mechanisms and downstream effectors 
including the TOR pathway and transcription factors such as SKN-1 [3], [4].  
The dramatic influence of DR on lifespan has inspired a broader notion 
that diet alone could modulate lifespan. Additionally, the highly conserved 
lifespan-extending effects of DR and mutations in genetic pathways, such as the 
IIS pathway, have lead to research for pharmaceutical mimetics and other dietary 
supplements that target these mechanisms and similarly extend life. In the next 
chapter, I will discuss how use of C. elegans has revealed new relationships 
between diet, drugs and lifespan. I will also review the effects of diet and drugs 
on C. elegans lifespan and how lifespan is likely modulated by combinatorial 
interactions between diet, drugs and the animal. I will then present my 
preliminary data that illustrates diet-specific drug effects on C. elegans and 
discuss future directions of this work. 
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Diet effects on C. elegans lifespan 
The “food limit” hypothesis has recently been challenged by the idea that 
“food quality” or composition may be a driving factor in modulating lifespan. 
Different types of bacteria influence C. elegans lifespan [5]–[10]. Recent work 
from our lab has shown that C. elegans lifespan is shortened on a Comamonas 
DA1877 diet when compared to E. coli OP50. In addition, Comamonas DA1877 
diet resulted in an accelerated developmental rate and reduced brood size. On a 
diet of killed Comamonas DA1877 or Comamonas DA1877 diluted with E. coli 
OP50, the C. elegans accelerated developmental rate persists supporting the 
interpretation that a dietary bacterial signal can modulate physiology [6]. Indeed, 
differences in life history traits of animals fed Comamonas DA1877 versus E. coli 
OP50 can be attributed to, at least in part, the content of vitamin B12 in bacteria. 
Vitamin B12, however, did not explain the differences in lifespan of animals fed 
these two bacteria [11]. Nonetheless, the shortened lifespan of C. elegans fed 
Comamonas DA1877 relative to E. coli OP50 is not observed upon diluting 
Comamonas DA1877 with E. coli OP50 consistent with the possibility that 
bacterial nutritional content, distinct from vitamin B12, causes the observed 
difference in lifespan [6].  
Genetically modifying the bacterial diet has revealed specific metabolic 
compounds and processes that affect lifespan. For instance, mutating an E. coli 
gene (aroD) involved in the biosynthesis of aromatic compounds, like folate, 
leads to increased lifespan. Adding folate back to the media shortened lifespan, 
comparable to wild-type, suggesting microbial folate synthesis may contribute to 
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C. elegans longevity. This hypothesis was further supported as inhibition of folate 
synthesis by a drug, sulfamethoxazole, led to a dose-dependent increase in C. 
elegans lifespan [12]. The ease with which the C. elegans diet can be genetically 
modified will allow for further investigation of metabolites, metabolic genes and 
pathways that contribute to lifespan [13], [14]. 
The use of C. elegans mutants has provided a powerful tool for unveiling 
mechanisms that modulate lifespan in response to diet. For instance, while there 
is no appreciable lifespan difference between wild-type animals fed E. coli OP50 
versus E. coli HT115, C. elegans with mutations in the TOR complex-2-specific 
factor Rictor are short lived when propagated on E. coli OP50 but long lived by 
76% on E. coli HT115 compared to wild-type animals [15]. One study used C. 
elegans mutants to determine that animals may employ adaptive strategies to 
cope with differences in these two E. coli strains [16]. Animals harboring a 
mutation in alh-6, a metabolic enzyme involved in the breakdown of proline, 
exhibit a 40% reduction in lifespan when fed OP50 compared to wild-type 
animals. However, when fed a diet of E. coli HT115, alh-6 mutants exhibited a 
lifespan similar to wild-type animals. Proline supplementation to an HT115 diet 
significantly reduced the lifespan of alh-6 mutants but not wild-type animals. 
Proline supplementation to an OP50 diet had no effect on alh-6 mutant lifespan. 
Additionally, accumulation of the ALH-6 substrate, P5C, a toxic intermediate of 
proline catabolism, leads to the premature aging phenotype of alh-6 mutants on 
an HT115 diet supplemented with proline. Together these data indicate that in 
wild-type animals, proline catabolism is activated on an E. coli OP50 diet and 
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ALH-6 facilitates the breakdown of P5C promoting survival. Without ALH-6, P5C 
accumulates and accelerates organismal aging [16]. The use of C. elegans 
mutants in this study thus revealed the importance of amino acid metabolism 
mediating lifespan on different diets.  
In addition to dietary differences in nutritional quality and production of 
bacterial metabolites, the pathogenicity and/or toxicity of bacteria can modulate 
lifespan. C. elegans propagated on heat killed or antibiotic-treated E. coli OP50 
have an extended lifespan compared to animals on live E. coli OP50 and show 
no signs of dietary restriction [17], [18]. Further, altering agar media that supports 
bacterial growth may shorten lifespan due to the induction of increased virulence 
of E. coli OP50 [9]. These studies agree with the influence of bacterial 
pathogenicity and toxicity in modulating lifespan, perhaps as a result of bacterial 
accumulation in the intestine [17], [19]–[21]. However, an opposing model 
suggests killing or altering growth media may affect the nutritional quality of 
bacteria. C. elegans propagated on a soil bacterium, Bacillus subtilis, has an 
extended lifespan compared to E. coli OP50. While this observation has been 
attributed to B. subtilis being less pathogenic than E. coli OP50, a recent study 
suggests the production of nitric oxide by B. subtilis enhances stress resistance, 
which in turn may contribute to increased lifespan of C. elegans [9], [22].  
Distinguishing dietary versus pathogenic effects on C. elegans lifespan is 
not trivial. For instance, C. elegans was reported to have an extended lifespan on 
E. coli deficient in coenzyme Q (GD1) when compared to wild-type E. coli [23]. 
However, supplementation of Q isoforms to the GD1 E. coli diet did not rescue 
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lifespan extension in C. elegans. Moreover, GD1 E. coli have respiratory 
defective metabolism, and respiratory deficient E. coli significantly increase 
lifespan of C. elegans when compared to the wild-type E. coli. Respiratory 
deficient E. coli were hypothesized to either lack products produced by 
respiratory competent E. coli strains, or produce fermentation products such as 
acetate, ethanol, etc. that modulate C. elegans metabolism [24]. Alternatively, 
respiratory defective GD1 E. coli were shown to colonize more slowly in the gut 
compared to E. coli OP50. Delayed gut colonization and decreased bacterial load 
were hypothesized to increase survival in C. elegans as bacterial proliferation in 
the gut contributes to mortality [17], [25]. This is further supported by C. elegans 
lifespan extension as a result of adding antibiotics that slow bacterial growth such 
as ampicillin, kanamycin, sulfamethoxasole or trimethoprim [12], [17], [26]. 
However, it is still unclear whether pathogenesis, a metabolic byproduct, or lack 
of a metabolite in the respiratory defective diet, or in response to antibiotic 
treatment, causes lifespan extension in C. elegans. 
Interestingly, bacteria can also modulate C. elegans lifespan through 
sensory mechanisms. Ablating olfactory and gustatory neurons in C. elegans can 
extend lifespan without affecting feeding behavior illustrating that perhaps even 
the “taste and smell” of food cues can stimulate changes in longevity [27], [28]. A 
recent genetic study illustrated different sensory neurons act with a neuromedin 
U receptor, nmur-1, to modulate lifespan effects in response to differences in 
lipopolysaccharide (LPS) on the cell wall of E. coli OP50 and E. coli HT115 [7]. 
Therefore, sensing different bacterial compositions may also influence lifespan. 
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Interactions between bacteria and C. elegans mirror the relationships 
between the gut microbiome and mammals. The mutualistic relationship between 
the gut microbiome and humans is important for host metabolism as nutrients 
from diet or supplied by the microbiota can affect human health. However, due to 
the genetic heterogeneity of mammals and the microbiome, long life and diverse 
diet, the mechanisms defining interactions between diet, the microbiome and 
aging are difficult to characterize. While it is too soon to know whether C. elegans 
will be a suitable model organism, the experimental tractability of the animal and 
the bacterial diet, short lifespan, and diverse bacterial food sources will certainly 
be advantageous tools for using C. elegans to form foundational hypothesis that 
can be tested in mammalian systems [13], [29]. For instance, C. elegans has 
been utilized to investigate how probiotics may promote health and longevity. 
Probiotic bacteria are living microorganisms that can be ingested and are 
believed to be beneficial on human health and longevity. Bifidobacteria, a lactic 
acid bacteria commonly used as a probiotic, suppresses C. elegans age-
associated sensitivities to bacterial infection and extends lifespan [30], [31]. 
Investigating further using C. elegans mutants, researchers found that 
bifidobacteria may extend lifespan via modulation of the p38 MAPK pathway and 
found that the cell wall plays a key role in extending lifespan [32]. Whether these 
mechanisms are similarly activated in higher eukaryotes remains to be explored. 
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Drug effects on C. elegans lifespan 
As a result of the potential for diet-mediated longevity, heroic efforts have 
been made to discover dietary and pharmacological interventions to extend the 
lifespan of C. elegans [33], [34]. For instance, one chemical, resveratrol, was 
identified in a screen measuring the biochemical activity of SIRT1, a protein 
shown to affect lifespan. SIRT1 promotes DR-mediated lifespan extension and 
regulates metabolic processes such as fatty acid oxidation in response to low 
energy states. The ability to allosterically induce SIRT1 activity opened the 
possibility of pharmacological mimetics and lead to the discovery of resveratrol, a 
polyphenol found in red wine and a potent SIRT1 activator. Interestingly, 
resveratrol increases lifespan in C. elegans, up to 18%, in Drosophila and in the 
short-lived fish Nothobranchius furzeri [35]–[37].  
The Free Radical Theory of Aging suggests that reactive oxygen species 
(ROS) produced as a byproduct of normal metabolism, particularly electron 
transport chain (ETC) function in mitochondria, can damage macromolecules 
such as nucleic acids, lipids and proteins by oxidation. Elevated ROS production 
over time results in aging and associated phenotypes [38]–[40]. Therefore, 
compounds that reduce ROS-mediated damage may delay aging and extend 
lifespan. Compounds such as antioxidants Vitamin E, superoxide dismutase and 
catalase mimetics, eukaryion-8 (EUK-8) and EUK-134, lipoic acid, propyl gallate, 
trolox and taxifolinhave been shown to extend lifespan although it is still unkown 
if the mechanisms of action are indeed through reduction of ROS-mediated 
damage [41]–[43].  
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One approach to understanding the mechanisms of aging is by screening 
compounds to identify chemicals that delay aging in C. elegans. This approach 
has been used to identify new compounds that have life-extending effects such 
as ethosuximide, an anticonvulsant used in treating seizures experienced in 
epileptic patients. Ethosuximide extends lifespan of wild-type animals by 17%. 
Analyzing structurally related chemicals, trimethadione and DAEBL, both of 
which also extend lifespan, revealed that lifespan extension is likely due to their 
anticonvulsant activity [44]. This was further supported by neurological 
phenotypes including fast body movement and pharyngeal pumping. While the 
direct mechanism of these drugs remains unknown, Evason et al. (2005) 
illustrated the drug-mediated lifespan extension was likely different from lifespan 
extending genetic pathways including the IIS pathway, mitochondrial function, 
caloric intake and neuronal activity. Similar compounds used in treatment of 
neurological disease have also been revealed to extend C. elegans lifespan 
including valproic acid, lithium and antidepressants mianserin, mirtazapine, 
methiothepin and cyproheptadine [45]–[47]. 
Drugs that are used to treat metabolic disease can also have lifespan 
extending effects. One DR-mimetic, metformin, increases lifespan independent of 
the IIS pathway and increases healthspan via activity of the cellular metabolic 
sensor, AMP-activated protein kinase (AMPK) [48]. Interestingly, metformin 
shortened lifespan of C. elegans cultured axenically (i.e. in the absence of E. 
coli) or on UV-killed E. coli OP50, suggesting the lifespan-extending effect of 
metformin requires live E. coli bacteria. Moreover, on E. coli HT115, metformin 
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shortened animal lifespan whereas metformin had no lifespan effect on animals 
cultured on E. coli HB101; both strains differ from the lifespan extension of 
metformin on E. coli OP50 [26]. Cabreiro et al. determined that metformin 
disrupts E. coli OP50 folate metabolism thereby reducing the amount of 
bioavailable folate and methionine and, as a result, indirectly slows aging in the 
animal by both initiating a dietary restricted state and activating AMPK. However, 
the toxicity of metformin directly affects worm lifespan as well, reducing lifespan 
at high doses. This study reveals that metformin, used to treat metabolic disease 
in humans, can act on both bacteria and the animal raising the question of 
whether metformin similarly affects the human gut microbiome.  
 
Measuring C. elegans lifespan and the use of FUdR 
Lifespan of C. elegans is defined by the time animals are alive from the L4 
larval stage (time = 0) (Fig. 1.1) until the day they are scored as dead, which 
typically occurs 2-3 weeks post-L4 stage. Measuring the maximum lifespan (i.e. 
time when 100% of animals are dead) and mean lifespan (i.e. time when 50% of 
animals are dead) is essential for quantifying aging of C. elegans. To measure 
lifespan, animals are maintained on standard growth media with a lawn of a 
single bacterial strain, typically E. coli OP50 or E. coli HT115, as the food source. 
Animals are scored as live or dead based on movement. At earlier times, when 
animals are less than 7-10 days adult, movement can be clearly seen. However, 
animals will significantly slow with age and move very little towards the end of life. 
During this time, death is scored as lack of movement upon prodding and the 
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animal is subsequently removed from the plate. Lifespan assays can also be 
performed in liquid and visualized using microscopy; however, these assays are 
not common as many complications arise with progeny contamination and the 
need to frequently transfer worms to fresh media throughout the duration of the 
assay [49], [50].  
During the lifespan assay, adult animals must be transferred onto new 
plates every day to prevent contamination with progeny. Alternatively, the drug 
2’-deoxy-5’fluorouridine (FUdR) is a DNA synthesis inhibitor commonly used to 
“sterilize” C. elegans and maintain a sterile aging population [51]–[53]. The use of 
FUdR can significantly lessen the amount of manual labor required to conduct 
lifespan assays and has been shown to have no effect on lifespan of wild-type 
animals [54], [55]. However, FUdR has been illustrated to influence lifespan 
under some conditions. For instance, lifespan of tub-1 and gas-1 mutants is 
extended in the presence of FUdR, and FUdR inhibits lifespan-extending effects 
of ash-2 RNAi on wild-type animals [56]–[58].  
FUdR inhibits thymidylate synthase (TS), an enzyme that uses 5,10-
methylenetetrahydrofolate (CH2THF) as a methyl donor to catalyze the 
conversion of dUMP to dTMP (Fig. 4.1). Upon entering the cell, FUdR is 
phosphorylated by thymidine kinase to form fluorodeoxyuridine monophosphate 
(FdUMP). FdUMP binds to the nucleotide-binding site of TS and forms a stable 
ternary complex with TS and CH2THF. As a result, access of dUMP to the 
nucleotide-binding site is blocked thereby inhibiting dTMP synthesis. The lack of 
dTMP leads to decreased levels of dTTP, and in turn, perturbs levels of other 
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FIGURE 4.1: Mechanism of thymidylate synthase inhibition by FUdR. 
Thymidylate synthase (TS) catalyzes the conversion of deoxyuridine 
monophosphate (dUMP) to deoxythymidine monophosphate (dTMP), with 5,10-
methylenetetrahydrofolate (CH2THF) as the methyl donor. The conversion of 
dUMP to dTMP is a product of the folate cycle whereby dihydrofolate reductase 
(DHFR) reduces dihydrofolate (DHF) to tetrahydrofolate (THF). THF is then 
converted to CH2THF via serine hydroxymethyltransferase (SHMT). The active 
metabolite of 5-fluorodeoxyuridine (FUdR), 5-fluorodeoxyuridine monophosphate 
(FdUMP) forms a stable ternary complex with TS and CH2THF blocking access 
of dUMP. As a result, dTMP synthesis is inhibited leading to nucleotide pool 
imbalances of deoxyuridine triphosphate (dUTP) and deoxythymidine 
triphosphate (dTTP) and a rise of misincorporation of dUTP into DNA. NADP, 
nicotinamide adenine dinucleotide phosphate  
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deoxynucleotides (dATP, dGTP, dCTP). Additionally, TS inhibition via FdUMP 
causes dUMP to accumulate, inducing a downstream self-defeating base 
excision repair process. Accumulated dUMP can lead to increased levels of 
dUTP. dUTP can be mis-incorporated into DNA and subsequently removed by 
the base excision repair enzyme, uracil-DNA clycosylase (UDG). Yet during the 
synthesis phase of DNA repair, dUTP is reincorporated and continues cycling 
through dUTP removal and incorporation until DNA strand breaks and loss of 
DNA integrity leads to cell death. Loss of function in genes involved in DNA 
synthesis and base excision repair may lead to FUdR resistance. For instance, 
knockdown of UDG significantly increases resistance to FUdR [59]. Similarly, 
decreased expression of dUTPase, the enzyme that catalyzes the reaction of 
dUMP to dUTP, also increases resistance to FUdR [60]–[62].  
Interestingly, FUdR has been shown to increase stress resistance and 
promote proteostasis in wild-type C. elegans [63]–[65]. Further, FUdR decreased 
age-dependent polyglutamine aggregation in a Huntington’s disease model [65]. 
Although lifespan was unaffected, FUdR was also shown to affect the metabolic 
profile of wild-type and daf-2 mutants [66]. The metabolic profile of C. elegans is 
extensively reorganized in the presence of daf-2 mutation. A daf-2 proteomic 
profile revealed upregulation of core intermediary metabolic pathways including 
glycolysis/gluconeogenesis, glycogenesis, pentose phosphate cycle, citric acid 
cycle, fatty acid B-oxidation, to name a few. The proteomic changes are very 
similar to that of dauers [67]. However, FUdR changes metabolite concentrations 
more dramatically in wild-type C. elegans, at least for some metabolites 
115
measured, than the daf-2 mutation. However, a few expected daf-2-dependent 
metabolic changes were unchanged after FUdR treatment, indicating that FUdR 
can interfere with metabolic changes that are a result of daf-2 mutation [66]. All 
together, these studies illustrate that the effects of FUdR extend further than 
simply inhibiting reproduction. FUdR increases stress resistance, proteostasis 
and can significantly alter metabolism, all of which are phenotypes observed in 
long-lived animals and promote increased lifespan of C. elegans. FUdR may 
indirectly influence lifespan and therefore skew the results of a lifespan assay 
examining the effects of a gene or compound on lifespan.  
 
 
 
 
  
116
PART II, CHAPTER 5 
 
RESULTS   
Diet-specific FUdR effects on C. elegans fertility and aging 
The sterility-inducing effect of FUdR has been exploited for lifespan 
assays and has been shown to have no effect on longevity of wild-type (N2) 
animals [53]–[55]. However, these studies were conducted on the standard E. 
coli diet. Therefore, we tested whether FUdR would affect lifespan of wild-type 
worms on a different diet consisting of Comamonas DA1877. In agreement with 
previous reports, N2 lifespan on the E. coli OP50 diet was unaffected by the 
presence of FUdR. Surprisingly, FUdR dramatically increased the mean lifespan 
of N2 animals by an average of 10 days on the Comamonas DA1877 diet. 
Further, FUdR treatment extended mean lifespan of N2 animals by an average of 
7 days on Comamonas DA1877 compared to E. coli OP50 (Fig. 5.1). These data 
illustrate FUdR affects C. elegans differently when fed two different diets: E. coli 
OP50 and Comamonas DA1877. I hypothesize that the lifespan extension of 
animals fed Comamonas DA1877 in the presence of FUdR is a result of FUdR 
altering Comamonas DA1877 metabolism, which in turn causes lifespan 
extension in C. elegans.  
 While performing lifespan assays, we observed that animals fed 
Comamonas DA1877 in the presence of FUdR laid many dead eggs, whereas 
animals on E. coli OP50 did not. This observation made us question whether 
animals fed Comamonas DA1877 may be more resistant to FUdR than animals 
fed E. coli OP50. Therefore, we qualitatively assessed at what concentration 
117
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 B 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.1: Diet-specific drug effects on C. elegans lifespan. (A) 
Representative lifespan of adult wild-type animals fed Comamonas DA1877 or E. 
coli OP50 in the presence of FUdR, as indicated. (B) Summary of three lifespan 
experiments. The mean represents the day at which 50% of the population is 
dead (i.e. mean lifespan) for a given condition, as indicated. The standard 
deviation (SD) is indicated for each condition (n ≈ 100 animals, per condition per 
experiment). 
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animals fed Comamonas DA1877 had viable progeny. We observed viable 
progeny of animals fed Comamonas DA1877 at a concentration of 10uM FUdR. 
Egg viability ceased, however, at 50uM FUdR. In contrast, animals fed E. coli 
OP50 had no viable progeny at 10uM FUdR.  
Next, we quantitatively measured the brood size of animals fed either E. 
coli OP50 or Comamonas DA1877 bacteria in the presence or absence of 10 mM 
FUdR. In agreement with previous observations [6], in the absence of FUdR, we 
found that animals fed Comamonas DA1877 have a slightly reduced brood size 
compared to animals fed E. coli OP50. Also in agreement with the reported 
sterile-inducing effects of FUdR, animals on E. coli OP50 in the presence of 
FUdR did not have viable progeny [54]. Remarkably, however, animals fed 
Comamonas DA1877 had an average brood size of 253 and 246 in the absence 
and presence of FUdR, respectively. There is no statistical difference between 
the brood sizes of animals fed Comamonas DA1877 in the absence or presence 
of FUdR (Fig. 5.2A). As observed qualitatively, on a higher concentration of 
50uM FUdR, C. elegans had no viable progeny when fed either bacterial diet. 
However, many dead eggs were present on the Comamonas DA1877 diet, while 
animals fed E. coli OP50 were sterile (Fig. 5.2B; data not shown).  Taken 
together, these data illustrate that animals fed E. coli OP50 are more sensitive to 
FUdR than animals fed Comamonas DA1877. 
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FIGURE 5.2: C. elegans fed Comamonas DA1877 require more FUdR to inhibit 
progeny production. Wild-type N2 animals were grown on two diets, Comamonas 
DA1877 and E. coli OP50, and in the presence of (A) 10µM and (B) 50µM FUdR, 
as indicated on the x-axis. Bars represent the average total number of progeny 
per animal (n = 30 animals). The SD is indicated in (A) for all animals combined.  
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Comamonas DA1877 are resistant to FUdR 
To determine if the bacterial diet itself was affected by FUdR treatment, 
we tested whether bacterial grow was affected by FUdR. Growth of E. coli OP50 
bacteria was sensitive to FUdR treatment in a dose-dependent manner; whereas, 
Comamonas DA1877 grew at a normal rate regardless of FUdR concentration 
(Fig. 5.3). Upon closer investigation of bacterial cell morphology, we observed E. 
coli OP50 bacterial cells had divided to form dramatically long bacteria after 
treatment with FUdR. Whereas Comamonas DA1877 bacteria also formed longer 
cells in the presence of FUdR, it was not to the extent of E. coli OP50 bacteria 
(Fig. 5.4). Taken together, these data illustrate that E. coli OP50 are more 
sensitive to FUdR than Comamonas DA1877. 
 
Comamonas DA1877 mutants are sensitive to FUdR 
 Our lab previously generated a Comamonas DA1877 mutant collection via 
transposon mutagenesis consisting of 5,760 mutants [11]. To determine why 
Comamonas DA1877 was resistant to FUdR, we screened this collection for 
mutant bacteria that, in the presence of FUdR, showed decreased growth and 
therefore sensitivity to the drug similar to E. coli OP50. We found 14 mutants that 
conferred no or little growth in the presence of FUdR. After retesting, three 
mutants did not repeat the FUdR-sensitive phenotype and three exhibited slow 
growth in the absence of FUdR and were subsequently discarded as hits. The 
remaining eight mutants were sequenced to verify and map transposon 
insertions and identify the disrupted genes (Fig. 5.5). Of the eight mutants, two 
121
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 5.3: Comamonas DA1877 are resistant to FUdR. Bacterial growth of 
Comamonas DA1877 (above) and E. coli OP50 (below) in the presence of FUDR, 
as indicated. Each line represents the average growth (y-axis, log 2 scale; n = 
three replicates) over time (x-axis) of replicate experiments, with the SD indicated 
for each time point.   
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FIGURE 5.4: Drug effects on bacterial morphology. Microscopic images of 
Comamonas DA1877 and E. coli OP50 bacterial cells in the presence of FUdR, 
as indicated. 
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mutants contained insertions in the same gene, an ATP-dependent DNA helicase, 
although at different locations in the gene. Four of the eight mutants contained 
disruptions in genes involved in DNA replication and repair, one in glycerolipid 
metabolism, one zinc metalloprotease, one C4-type zinc-finger protein, and one 
is a gene of unknown identification or function. Therefore in total, seven unique 
genes were identified that, when disrupted, conferred Comamonas DA1877 
sensitive to FUdR (Fig. 5.5; Table 5.1). Given the number of genes involved in 
DNA replication and repair that influenced FUdR sensitivity, I hypothesize that 
DNA repair and replication are important mechanisms that influence bacterial 
sensitivity to FUdR.  
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FIGURE 5.5: Comamonas DA1877 mutants are sensitive to FUdR. 
Representative pictures from an experimental spot retest assay. Comamonas 
DA1877, E.coli OP50 controls and Comamonas mutant bacteria hits (as listed; 
1:10,000 dilution) are grown in the absence (-) or presence (+) of 800µM FUdR.  
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Table 5.1: Comamonas DA1877 mutants sensitive to FUdR compared to wild 
type Comamonas DA1877. Eight mutants showed normal growth on standard LB 
solid media but little to no growth when grown on LB and FUdR. The predicted 
gene and or function for each mutant are listed (gene/function) as well as 
putative biological processes for which each gene participates (subsystem). 
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PART II MATERIALS AND METHODS 
 
C. elegans maintenance 
The N2 (Bristol) strain was used as the wild-type strain, and was maintained at 
20°C using standard C. elegans techniques [68]. All bacteria used to seed 
Nematode Growth Media (NGM) plates were grown from a single colony on solid 
Luria Broth (LB) media plates (10g tryptone, 5g yeast extract, 10g NaCl, 15g 
agar in 1L MilliQ water; pH 7.0) at 37°C, shaking overnight. Plates were seeded 
2-3 days before use.  
 
Phenotypic Assays 
For all diet-specific assays, animals were grown on the appropriate diet for at 
least one generation prior to the assay.  
Brood sizes were determined by placing individual L4 animals onto plates 
containing different diets and/or drug, as indicated. Animals were transferred 
daily to new plates, respectively, and number of offspring on the plates was 
counted.  
For lifespan assays, L4 animals were transferred onto NGM pates (approx. 
25 animals per plate; four plates per condition) seeded with the diet and/or FUDR, 
as indicated. Animals were transferred to new NGM plates seeded with the 
appropriate bacteria daily until progeny production seized [49]. Every day 
thereafter, animals were checked for movement and pharyngeal pumping. If 
pumping or movement was not observed, animals were lightly prodded with 
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platinum wire. If after prodding no response was detected, they were considered 
dead, scored and removed. Animals that died from vulval bursting were censored. 
 
Bacterial Growth in Liquid Media 
Single colony inoculated cultures were grown in LB media (see above) overnight 
at 37°C, shaking. The following day, bacteria were transferred to fresh LB media 
with a starting OD no greater than 0.07. Each culture was grown at 37°C, 
shaking, with supplemented drug or nutrient as indicated. Culture volume was 
approximately 10% of the flask volume. Samples from each culture were 
measured at times indicated for each experiment. The optical density of the 
overnight culture was determined using an Eppendorf BioPhotometer Plus at 
600nm wavelength. As necessary, samples were diluted to ensure a measured 
OD did not exceed 0.600 for optimized accuracy, linearity and reproducibility. 
Images of bacteria were taken using a DeltaVision Deconvolution Florescence 
Microscope. 
 
Comamonas DA1877 mutant screen 
The Comamonas DA1877 mutant library was generated previously as described 
in [11]. The library was spotted onto Singer Plusplates containing LB and 
gentamicin (final concentration=10µg/mL) in a 1536-colony format using the 
RoToR HAD robot (Singer Instruments). 1536-colony format plates from 96-well 
glycerol stocks were generated using methods modified from [69]. In summary, 
the RoToR HAD robot uses disposable plastic pads with 96, 384 or 1536 pins to 
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precisely transfer bacteria onto solid agar plates. To build the 1536-colony “quad 
array,” 96-colony plates of the Comamonas DA1877 mutant library are first 
generated by spotting from 96-well plates of glycerol stocks onto solid agar 
plates. 96-colony solid plates were stored in plastic bags and incubated at 37°C 
overnight. A single transfer from four separate 96-colony plates is then used to 
build a 384-colony plate in which each Comamonas DA1877 mutant is present 
once. These plates were then incubated at 37°C for approximately eight hours. 
Finally, four transfers from the same 384-colony plate are used to create the 
1536-colony plate in which each Comamonas DA1877 is present in 
quadruplicate. Comamonas DA1877 mutant strains are grown on both LB and 
LB-gentamicin at 25°C overnight. Each 1536-colony plate was then replicated 
onto two plates: LB-gentamicin and LB-gentamicin-FUdR. 800µM FUdR was 
used as growth of E. coli OP50 at this concentration was strongly inhibited, 
whereas Comamonas DA1877 growth was not, and therefore easing visual 
screening for changes in bacterial growth. Replica plates were stored in bags 
and grown up to two days at 20°C. A hit was considered positive if at least two of 
the four colonies showed little to no growth on LB-gentamicin-FUdR but not LB-
gentamicin plates. 
Positive hits were retested by spotting bacteria onto LB-gentamicin and 
LB-gentamicin with 400µM and 800µM FUdR. Briefly, each mutant strain was 
grown in liquid LB media with gentamicin at 37°C overnight to saturation. Each 
culture was then diluted with LB media so that OD600=1. 10-fold serial dilutions 
were then prepared and 10µL from each dilution (from 10-3 to 10-6) was spotted 
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onto LB-gentamicin and LB-gentamicin-FUdR solid plates. Plates were allowed 
to dry and then stored at 37°C overnight. The retest was considered positive if 
diluted mutant bacteria grew normally on LB-gentamicin, but little to no growth 
was observed on LB-gentamicin-FUdR.  
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PART II, CHAPTER 6 
 
DISCUSSION  
 In this study, we report that FUdR can have differential effects on C. 
elegans reproduction and lifespan in a bacteria-dependent manner. FUdR can 
also cause dramatic lifespan extension to wild-type C. elegans on a Comamonas 
DA1877 diet. The use of FUdR in measuring C. elegans lifespan was historically 
exploited for its ability to inhibit progeny production and thus maintain a sterile 
adult population. The amount of FUdR used for lifespan assays ranges 
dramatically in the literature, from 1uM to 400uM. However, our data, in 
agreement with previously published studies, illustrate that FUdR should be used 
with caution when measuring C. elegans lifespan and, in particular, when 
examining lifespan on bacterial diets other than E. coli OP50. For experiments 
where FUdR must be utilized, previous reports suggest a low dose concentration 
of 1uM will cause sterility yet have minimal influence on lifespan [56], [70]. 
However, these studies analyzed FUdR concentration effects on animals with a 
diet of E. coli OP50. We demonstrate that any concentration less than 10uM will 
have no sterility-inducing effect on animals fed Comamonas DA1877. Taken 
together, the genotype of the animal and bacterial diet should be considered in 
determining the effective dose of FUdR. Additionally, as there may be 
interactions between FUdR, bacteria and the animal, effects of the bacterial diet 
on C. elegans physiology should be validated in the absence of FUdR. 
Environmental conditions, including temperature, also influence the lifespan of C. 
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elegans. FUdR may interact with other environmental, dietary or genetic factors 
and should be tested when used for assays, as any observed effects of these 
factors on C. elegans physiology may be dependent on FUdR.   
 
FUdR differentially affects bacterial growth of E. coli OP50 and 
Comamonas DA1877 
The function of FUdR inhibiting the TS enzyme is conserved across many 
species. As a result, the mechanism of FUdR has been exploited to prevent 
reproduction in C. elegans. However, due to the conservation of its target, FUdR 
likely affects bacterial TS enzyme and subsequently bacterial DNA synthesis. 
Therefore, one should not assume that FUdR is only affecting C. elegans TS 
enzyme when utilized for assays. We show that FUdR inhibits E. coli OP50 
growth and dramatically changes cell morphology, whereas, surprisingly, 
Comamonas DA1877 growth appears largely unaffected.  
Why does FUdR affect E. coli OP50 but not Comamonas DA1877 growth? 
One hypothetical explanation for Comamonas DA1877 resistance to FUdR is that 
FUdR never actually reaches the bacterial TS enzyme. FUdR could fail to enter 
the cell, be efficiently effluxed from the cell, and/or degraded by enzymes made 
by Comamonas DA1877. Although, bacterial elongation and the lifespan 
extension of C. elegans on Comamonas DA1877 in the presence of FUdR 
suggests FUdR is affecting the bacteria. Nonetheless, our data is not definitive. 
Comamonas DA1877 may also be resistant to FUdR due to TS mutation, such 
that there is reduced affinity for the ligand, FdUMP. Reduced affinity for FdUMP 
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has been suggested to explain, at least in part, FUdR resistance in some cell 
lines [71], [72].  
To try and address this question, we screened the Comamonas DA1877 
mutant library for bacteria that conferred sensitivity to FUdR. From this 
experiment, we found mutants with disruptions in genes involved in DNA 
synthesis and repair, bacterial metabolism and a few with unknown function. 
Whether these genes contribute to Comamonas DA1877 resistance to FUdR 
remains unexplored. However, thymineless death, a term used to describe the 
depletion of TTP pools following TS inhibition, is exacerbated in E. coli lacking 
proteins involved in DNA repair mechanisms, including UvrD helicase and 
RecBCD, genes identified in our screen [73], [74]. UvrD helicase is involved in 
nucleotide excision repair, mismatch repair, and dismantles RecA on single 
strand DNA thus inhibiting homologous recombination [75]. RecBCD is a double-
strand exonuclease and catalyst of double-strand-break repair by homologous 
recombination [73]. Additionally, RecA recombinase, a central protein in 
homologous recombination, also activates bacterial DNA-damage, or SOS, 
response by indirectly upregulating SOS-response genes. Elongated, 
filamentous bacterial cells are a characteristic phenotype associated with the 
SOS response [76], [77]. This morphological change is also observed in our 
bacterial cultures incubated with FUdR, indicating that FUdR is likely initiating the 
SOS response (Fig. 5.4). With this knowledge, perhaps Comamonas DA1877 
DNA repair pathways are more efficient at repairing DNA allowing these bacteria 
to be more tolerant of FUdR-induced damage. Mutating these genes may not 
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render Comamonas DA1877 sensitive to FUdR specifically, but rather cause the 
bacteria to be sensitized to any drug that can disrupt DNA.  
The genotype of the E. coli OP50 strain should be considered when 
exploring why this strain is sensitive to FUdR compared to Comamonas DA1877. 
E. coli OP50 is a mutant strain of E. coli that, although mechanistically unknown, 
renders the OP50 strain a uracil auxotroph. The standard NGM medium used to 
propagate C. elegans has limited uracil and therefore prevents overgrowth of the 
bacterial lawn, which could obscure worm movement [68]. For this reason, E. coli 
OP50 was used as the food source during the establishment of C. elegans as a 
model organism and subsequently remained the laboratory standard. However, 
uracil auxotrophy occurs through inactivating enzymes involved in de novo 
pyrimidine synthesis, such as orotidylate decarboxylase (OMP decarboxylase) 
and carbamoyl phosphate synthetase II (CPS II), or by inhibiting nucleotide 
transporters involved in pyrimidine salvage pathways. Uridine nucleotides are 
precursors for de novo synthesis of thymine nucleotides. Whether the uracil 
auxotrophic phenotype of E. coli OP50 enhances its sensitivity to FUdR has not 
been explored. Additionally, it is unknown what other mutations exist in the E. coli 
OP50 genome and whether those may also contribute to its sensitivity to FUdR. 
It would be of interest, then, to test wild-type E. coli and compare its FUdR 
sensitivity to that of E. coli OP50. 
As FUdR alters bacterial growth and physiology and is a known inhibitor of 
thymidylate synthase, an enzyme involved in folate metabolism, it is highly likely 
that FUdR will modulate metabolic processes of E. coli OP50 and Comamonas 
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DA1877. FUdR has been illustrated to cause changes in the metabolic profile of 
wild-type and mutant daf-2 C. elegans. We illustrate that mutations in at least one 
metabolic enzyme, 1-acyl-sn-glycerol-3-phosphate acylteransferase, render 
Comamonas DA1877 sensitive to FUdR (Table 5.1). The next step will be to 
determine whether reproduction or lifespan of C. elegans is altered when 
propagated on the identified Comamonas DA1877 mutant bacteria, either in the 
absence or presence of FUdR.  
 
FUdR effects on C. elegans are diet-dependent 
Our data shows FUdR affects C. elegans reproduction and lifespan in a 
diet-dependent manner. However, we do not know if the phenotypic response is 
mediated through the bacteria, from direct interactions between FUdR and the 
animal, or both. One hypothesis is that Comamonas DA1877 renders FUdR 
ineffective either by metabolizing it or by making or expressing an unknown 
component, albeit metabolite, enzyme, etc., that effectively “neutralizes” the drug. 
This would be consistent with our data demonstrating Comamonas DA1877 
resistance to FUdR and continued C. elegans reproduction in the presence of 
FUdR when fed Comamonas DA1877. To determine this, one should first 
examine the effects of FUdR and killed bacteria on C. elegans reproduction and 
lifespan. Measuring C. elegans phenotypes in the presence of killed bacteria and 
FUdR will address whether resistance of Comamonas DA1877 fed animals to 
FUdR is mediated through bacterial inactivation of the compound. For instance, if 
metabolically active Comamonas DA1877 bacteria “neutralize” FUdR, one might 
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expect animals to have increased sensitivity to FUdR in the presence of killed 
Comamonas DA1877. In addition, it may be of importance to know how much 
FUdR is reaching the animal through the NGM media in the presence or absence 
of live bacteria. A report recently illustrated that less FUdR is absorbed by C. 
elegans in the presence of live E. coli OP50 bacteria. In addition, the 
concentration of FUdR in NGM medium with live E. coli OP50 present decreased 
faster than with dead bacteria. These data illustrate bacteria can metabolize the 
drug and lower absorption by C. elegans [78]. Interestingly, this was observed for 
E. coli OP50, raising the question as to whether this will be similarly observed for 
Comamonas DA1877 or whether Comamonas DA1877 will have greater 
efficiency in degrading FUdR, as animals can reproduce in the presence of 
higher amounts of FUdR on live Comamonas DA1877 bacteria (Fig. 5.2).  
Further, it is unknown whether the bacterial-specific FUdR effects on C. 
elegans reproduction are the same as on lifespan. For instance, the mechanism 
that allows C. elegans to reproduce on Comamonas DA1877 in the presence of 
FUdR may be different from the lifespan extending effects of FUdR. Perhaps 
modulation of these two phenotypes requires different mechanisms. The data 
presented here serve as a foundation from which further hypotheses can be 
derived. While not definitively proven, it is highly likely that bacteria modify the C. 
elegans response to FUdR, through what mechanism remains unexplored. 
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Future directions 
The chemotherapeutic 5-FU is an antimetabolite that is broken down to 
FdUMP and inhibits TS similarly to FUdR. In addition, 5-FU can be converted to 
FUTP and FdUTP, which disrupt RNA synthesis [79]. 5-FU is one of the most 
effective drugs used to treat colorectal cancer and its use has been associated 
with changes in the intestinal microbiota [80]–[83]. Human patients treated with 
5-FU and other fluoropyrimidines illustrate severe diarrhea, likely due to the 
killing of commensal bacteria in the gut [81]. The significant side effects of 
chemotherapeutic agents on the intestinal microbiota have increased interest in 
discovering interventions to reduce intestinal-induced toxicities. For instance, 
camptothecin, a human topoisomerase I inhibitor used in the treatment of 
colorectal cancer, causes severe diarrhea. However, inhibiting the B-
glucuronidase enzyme in bacterial cells, including E. coli, alleviates drug toxicity 
[84]. Other interventions such as probiotic treatment have also been prescribed 
to alleviate severe diarrhea in patients under treatment for colon cancer [85].  
We have illustrated that C. elegans reproduction and lifespan can serve as 
proxies to investigate bacterial-specific FUdR effects. Is the bacterial-specific 
effect limited to FUdR? Can other DNA synthesis inhibitors or chemotherapeutics 
modulate C. elegans physiology in a bacteria-specific manner? The interactions 
between the host and microbe comprise complex networks; however, with 
genetic tools, such as RNAi and bacterial mutant collections, one can manipulate 
both the host and the microbe to begin dissecting these interactions.  C. elegans 
can be propagated on a variety of bacterial diets [6], [8], [86]. In addition, C. 
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elegans have already been utilized for drug discovery and screening of small-
molecule compounds to treat disease [87]. The high conservation of molecular 
pathways involved in cancer means that C. elegans data could be predictive for 
drug-target interactions in mammals [88]. The advantages of C. elegans as a 
model to examine the interaction between bacteria, chemotherapeutic agents, 
and their targets may be beneficial for gaining insight into counterparts in 
mammals.  
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